Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N Engl J Med [Internet]. Massachusetts Medical Society; 2010;363:711–23. Available from: https://doi.org/10.1056/NEJMoa1003466
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381:1535–46.
Sharpless NE. COVID-19 and cancer. Science [Internet]. American Association for the Advancement of Science; 2020 [cited 2020 Jun 29];368:1290. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32554570
Section S, Epidemic TO. Global Cancer Facts & Figures 4th Edition. 2018;
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2018). Global Cancer Observatory: Cancer Tomorrow. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/tomorrow, accessed [DD Month YYYY]. [Internet]. [cited 2019 Jul 29].
Atun R, Bhakta N, Denburg A, Frazier AL, Friedrich P, Gupta S, et al. Sustainable care for children with cancer: a Lancet Oncology Commission. Lancet Oncol [Internet]. Elsevier; 2020 [cited 2020 Aug 1];21:e185–224. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32240612
Delavar A, Barnes JM, Wang X, Johnson KJ. Associations between Race/Ethnicity and US Childhood and Adolescent Cancer Survival by Treatment Amenability. JAMA Pediatr. American Medical Association; 2020.
Jaffe SA, Myers O, Meisner ALW, Wiggins CL, Hill DA, Mcdougall JA. Relationship between Insurance Type at Diagnosis and Hepatocellular Carcinoma Survival. 2020;1–9.
Siegel RL, Miller KD. Cancer Statistics , 2019. 2019;69:7–34.
Gonzales G, Zinone R. Cancer diagnoses among lesbian, gay, and bisexual adults: results from the 2013–2016 National Health Interview Survey. Cancer Causes Control [Internet]. 2018 [cited 2019 Jun 19];29:845–54. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30043193
DeSantis CE, Miller KD, Goding Sauer A, Jemal A, Siegel RL. Cancer statistics for African Americans, 2019. CA Cancer J Clin [Internet]. 2019 [cited 2019 Feb 15]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/30762872
Morawski BM, Weir HK, Johnson CJ. Five-Year U.S. Trends in the North American Cancer Survival Index, 2005–2014. Am J Prev Med. Elsevier Inc.; 2020;58:453–6.
Henley SJ, Ward EM, Scott S, Ma J, Anderson RN, Firth AU, et al. Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics. Cancer. 2020;2225–49.
Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin [Internet]. 2020;0:1–20. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32133645
A B, F S, R B. Prostate Cancer in Young Men: An Emerging Young Adult and Older Adolescent Challenge. Cancer [Internet]. Cancer; 2020 [cited 2020 Jun 30];126. Available from: https://pubmed.ncbi.nlm.nih.gov/31553489/
Torre L, Street W, Bray F. THE CANCER.
Mariotto AB, Enewold L, Zhao J, Zeruto CA, Yabroff KR. Medical Care Costs Associated with Cancer Survivorship in the United States. Cancer Epidemiol Biomarkers Prev [Internet]. American Association for Cancer Research; 2020 [cited 2020 Jun 30]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/32522832
Collins FS, Anderson JM, Austin CP, James F, Birnbaum LS, Briggs P, et al. Basic science : Bedrock of pro gress Join the. Science (80- ). 2016;351:1405.
Galkina Cleary E, Beierlein JM, Khanuja NS, McNamee LM, Ledley FD. Contribution of NIH funding to new drug approvals 2010–2016. Proc Natl Acad Sci. 2018;115:201715368.
AACR. AACR Cancer Progress Report. Aacr. 2017;
Cieslik M, Chinnaiyan AM. Global genomics project unravels cancer’s complexity at unprecedented scale. Nature [Internet]. Nature Publishing Group; 2020 [cited 2020 Jun 30];578:39–40. Available from: http://www.nature.com/articles/d41586-020-00213-2
Campbell PJ, Getz G, Korbel JO, Stuart JM, Jennings JL, Stein LD, et al. Pan-cancer analysis of whole genomes. Nature. 2020;578:82–93.
Rheinbay E, Nielsen MM, Abascal F, Wala JA, Shapira O, Tiao G, et al. Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. Nature. 2020;578:102–11.
Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Tian Ng AW, Wu Y, et al. The repertoire of mutational signatures in human cancer. Nature. 2020;578:94–101.
Li Y, Roberts ND, Wala JA, Shapira O, Schumacher SE, Kumar K, et al. Patterns of somatic structural variation in human cancer genomes. Nature. 2020;578:112–21.
Gerstung M, Jolly C, Leshchiner I, Dentro SC. 泛癌The evolutionary history of 2 , 658 cancers. Nature. 2020;578.
Susswein LR, Marshall ML, Nusbaum R, Vogel Postula KJ, Weissman SM, Yackowski L, et al. Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing. Genet Med [Internet]. 2016 [cited 2019 Jul 9];18:823–32. Available from: http://www.nature.com/articles/gim2015166
Huang K-L, Mashl RJ, Wu Y, Ritter DI, Wang J, Oh C, et al. Pathogenic Germline Variants in 10,389 Adult Cancers. Cell [Internet]. 2018 [cited 2019 Jul 9];173:355-370.e14. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0092867418303635
Kawanishi S, Ohnishi S, Ma N, Hiraku Y, Murata M. Crosstalk between DNA Damage and Inflammation in the Multiple Steps of Carcinogenesis. Int J Mol Sci [Internet]. 2017 [cited 2018 Jun 11];18:1808. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28825631
Baselga J, Bhardwaj N, Cantley LC, DeMatteo R, DuBois RN, Foti M, et al. AACR Cancer Progress Report 2015. Clin. Cancer Res. United States; 2015. page S1-128.
WA F, Y D, SE J, ML H, DR T, E H, et al. Altered Chromosomal Topology Drives Oncogenic Programs in SDH-deficient GISTs. Nature [Internet]. Nature; 2019 [cited 2020 Jun 30];575. Available from: https://pubmed.ncbi.nlm.nih.gov/31666694/
Popejoy, Alice B., Fullerton SM. Genomics is falling. Nature. 2016;538:161–4.
Sirugo G, Williams SM, Tishkoff SA. The Missing Diversity in Human Genetic Studies. Cell [Internet]. Elsevier Inc.; 2019;177:26–31. Available from: https://doi.org/10.1016/j.cell.2019.02.048
Mcgranahan N, Swanton C. Review Clonal Heterogeneity and Tumor Evolution : Past , Present , and the Future. Cell [Internet]. Elsevier Inc.; 2017;168:613–28. Available from: http://dx.doi.org/10.1016/j.cell.2017.01.018
Hawkins ED, Duarte D, Akinduro O, Khorshed RA, Passaro D, Nowicka M, et al. T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments. Nature. 2016;
Zeng Q, Michael IP, Zhang P, Saghafinia S, Knott G, Jiao W, et al. Synaptic proximity enables NMDAR signalling to promote brain metastasis. Nature [Internet]. Nature Publishing Group; 2019 [cited 2020 Jun 30];573:526–31. Available from: http://www.nature.com/articles/s41586-019-1576-6
Y Z, A W, N C, CE P, K X, GM A, et al. Polyunsaturated Fatty Acids From Astrocytes Activate PPARγ Signaling in Cancer Cells to Promote Brain Metastasis. Cancer Discov [Internet]. Cancer Discov; 2019 [cited 2020 Jun 30];9. Available from: https://pubmed.ncbi.nlm.nih.gov/31578185/
A T, B F, V R, JM U, B S, A S, et al. Metabolic Heterogeneity Confers Differences in Melanoma Metastatic Potential. Nature [Internet]. Nature; 2020 [cited 2020 Jun 30];577. Available from: https://pubmed.ncbi.nlm.nih.gov/31853067/
Sun Y. Tumor microenvironment and cancer therapy resistance. Cancer Lett [Internet]. Elsevier Ireland Ltd; 2016;380:205–15. Available from: http://dx.doi.org/10.1016/j.canlet.2015.07.044
References 51-100
Swanton C. Take lessons from cancer evolution to the clinic. Nature [Internet]. Nature Publishing Group; 2020 [cited 2020 Jun 30];581:382–3. Available from: http://www.nature.com/articles/d41586-020-01347-z
AbdulJabbar K, Raza SEA, Rosenthal R, Jamal-Hanjani M, Veeriah S, Akarca A, et al. Geospatial immune variability illuminates differential evolution of lung adenocarcinoma. Nat Med [Internet]. Nature Publishing Group; 2020 [cited 2020 Jun 30];1–9. Available from: http://www.nature.com/articles/s41591-020-0900-x
Joshi K, de Massy MR, Ismail M, Reading JL, Uddin I, Woolston A, et al. Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer. Nat Med [Internet]. Nature Publishing Group; 2019 [cited 2020 Jun 30];25:1549–59. Available from: http://www.nature.com/articles/s41591-019-0592-2
Ghorani E, Reading JL, Henry JY, Massy MR de, Rosenthal R, Turati V, et al. The T cell differentiation landscape is shaped by tumour mutations in lung cancer. Nat Cancer [Internet]. Nature Publishing Group; 2020 [cited 2020 Jun 30];1:546–61. Available from: http://www.nature.com/articles/s43018-020-0066-y
Rosenthal R, Cadieux EL, Salgado R, Bakir M Al, Moore DA, Hiley CT, et al. Neoantigen-directed immune escape in lung cancer evolution. Nature [Internet]. Nature Publishing Group; 2019 [cited 2020 Jun 30];567:479–85. Available from: http://www.nature.com/articles/s41586-019-1032-7
López S, Lim EL, Horswell S, Haase K, Huebner A, Dietzen M, et al. Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution. Nat Genet [Internet]. Nature Publishing Group; 2020 [cited 2020 Jun 30];52:283–93. Available from: http://www.nature.com/articles/s41588-020-0584-7
Davidson NE, Armstrong SA, Coussens LM, Cruz-Correa MR, DeBerardinis RJ, Doroshow JH, et al. AACR Cancer Progress Report 2016. Clin Cancer Res. United States; 2016;22:S1–137.
Sicklick JK, Kato S, Okamura R, Schwaederle M, Hahn ME, Williams CB, et al. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat Med [Internet]. Nature Publishing Group; 2019 [cited 2019 Jun 19];25:744–50. Available from: http://www.nature.com/articles/s41591-019-0407-5
Pishvaian MJ, Blais EM, Brody JR, Lyons E, DeArbeloa P, Hendifar A, et al. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial. Lancet Oncol [Internet]. Elsevier; 2020 [cited 2020 Jun 30];21:508–18. Available from: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30074-7/fulltext
Creed JH, Berglund AE, Rounbehler RJ, Awasthi S, Cleveland JL, Park JY, et al. Commercial Gene Expression Tests for Prostate Cancer Prognosis Provide Paradoxical Estimates of Race-Specific Risk. Cancer Epidemiol Biomarkers Prev [Internet]. Cancer Epidemiol Biomarkers Prev; 2020 [cited 2020 Aug 1];29:246–53. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31757784
Ge H, Wang X, Yuan X, Xiao G, Wang C, Deng T, et al. The epidemiology and clinical information about COVID-19. Eur J Clin Microbiol Infect Dis [Internet]. Springer; 2020 [cited 2020 Aug 1];39:1011–9. Available from: http://link.springer.com/10.1007/s10096-020-03874-z
Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature [Internet]. Nature Publishing Group; 2020 [cited 2020 Aug 1];583:459–68. Available from: http://www.nature.com/articles/s41586-020-2286-9
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell [Internet]. Elsevier; 2020 [cited 2020 Aug 1];181:271-280.e8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32142651
He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med [Internet]. Nature Publishing Group; 2020 [cited 2020 Aug 3];26:672–5. Available from: http://www.nature.com/articles/s41591-020-0869-5
Gupta A, Madhavan M V., Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. Nat Med [Internet]. Nature Publishing Group; 2020 [cited 2020 Jul 15];26:1017–32. Available from: http://www.nature.com/articles/s41591-020-0968-3
Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol [Internet]. Nature Publishing Group; 2020 [cited 2020 Aug 1];20:363–74. Available from: http://www.nature.com/articles/s41577-020-0311-8
Stokes EK, Zambrano LD, Anderson KN, Marder EP, Raz KM, El Burai Felix S, et al. Coronavirus Disease 2019 Case Surveillance — United States, January 22–May 30, 2020. MMWR Morb Mortal Wkly Rep [Internet]. 2020 [cited 2020 Aug 2];69:759–65. Available from: http://www.cdc.gov/mmwr/volumes/69/wr/mm6924e2.htm?s_cid=mm6924e2_w
Goyal MK, Simpson JN, Boyle MD, Badolato GM, Delaney M, Mccarter R, et al. Prepublication Release Racial/Ethnic and Socioeconomic Disparities of SARS-CoV-2 Infection Among Children. Pediatrics [Internet]. 2020 [cited 2020 Aug 15]; Available from: http://www.aappublications.org/news
Moghadas SM, Fitzpatrick MC, Sah P, Pandey A, Shoukat A, Singer BH, et al. The implications of silent transmission for the control of COVID-19 outbreaks. Proc Natl Acad Sci U S A [Internet]. National Academy of Sciences; 2020 [cited 2020 Aug 1];117:17513–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32632012
Furukawa NW, Brooks JT, Sobel J. Evidence Supporting Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 While Presymptomatic or Asymptomatic. Emerg Infect Dis [Internet]. 2020 [cited 2020 Aug 1];26. Available from: http://wwwnc.cdc.gov/eid/article/26/7/20-1595_article.htm
Lyu W, Wehby GL. Community Use Of Face Masks And COVID-19: Evidence From A Natural Experiment Of State Mandates In The US. Health Aff [Internet]. Health Affairs; 2020 [cited 2020 Aug 1];10.1377/hlthaff. Available from: http://www.healthaffairs.org/doi/10.1377/hlthaff.2020.00818
Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. Solomon CG, editor. N Engl J Med [Internet]. Massachusetts Medical Society; 2020 [cited 2020 Aug 2];NEJMcp2009575. Available from: http://www.nejm.org/doi/10.1056/NEJMcp2009575
Mehta V, Goel S, Kabarriti R, Cole D, Goldfinger M, Acuna-Villaorduna A, et al. Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. Cancer Discov [Internet]. American Association for Cancer Research; 2020 [cited 2020 Jul 16];10:935–41. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32357994
Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov [Internet]. American Association for Cancer Research; 2020 [cited 2020 Jul 16];10:783–91. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32345594
Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. OpenSAFELY: factors associated with COVID-19 death in 17 million patients. Nature [Internet]. Springer US; 2020; Available from: http://dx.doi.org/10.1038/s41586-020-2521-4
Rivera DR, Peters S, Panagiotou OA, Shah DP, Kuderer NM, Hsu C-Y, et al. Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: A COVID-19 and Cancer Consortium (CCC19) cohort study. Cancer Discov. 2020;1.
Menni C, Valdes AM, Freidin MB, Sudre CH, Nguyen LH, Drew DA, et al. Real-time tracking of self-reported symptoms to predict potential COVID-19. Nat Med [Internet]. Nature Publishing Group; 2020 [cited 2020 Aug 2];26:1037–40. Available from: http://www.nature.com/articles/s41591-020-0916-2
Drew DA, Nguyen LH, Steves CJ, Menni C, Freydin M, Varsavsky T, et al. Rapid implementation of mobile technology for real-time epidemiology of COVID-19. Science [Internet]. American Association for the Advancement of Science; 2020 [cited 2020 Aug 2];368:1362–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32371477
N T, H B, X C, J G, D L, Z S. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost [Internet]. J Thromb Haemost; 2020 [cited 2020 Aug 2];18. Available from: https://pubmed.ncbi.nlm.nih.gov/32220112/
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19 — Preliminary Report. N Engl J Med [Internet]. Massachusetts Medical Society; 2020 [cited 2020 Aug 2];NEJMoa2007764. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2007764
Group TRC. Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report. N Engl J Med [Internet]. Massachusetts Medical Society; 2020 [cited 2020 Aug 2];NEJMoa2021436. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2021436
Kaufman HW, Chen Z, Niles J, Fesko Y. Changes in the Number of US Patients With Newly Identified Cancer Before and During the Coronavirus Disease 2019 (COVID-19) Pandemic. JAMA Netw Open [Internet]. American Medical Association; 2020 [cited 2020 Aug 15];3:e2017267. Available from: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2768946
Gewin V. The career cost of COVID-19 to female researchers, and how science should respond. Nature [Internet]. 2020 [cited 2020 Aug 15];583:867–9. Available from: http://www.nature.com/articles/d41586-020-02183-x
Woolston C. ‘It’s like we’re going back 30 years’: how the coronavirus is gutting diversity in science. Nature [Internet]. 2020 [cited 2020 Aug 15]; Available from: http://www.nature.com/articles/d41586-020-02288-3
COVID-19 and Clinical Trials: The Medidata Perspective. Release 7.0. 2020;
Unger JM, Blanke CD, LeBlanc M, Hershman DL. Association of the Coronavirus Disease 2019 (COVID-19) Outbreak With Enrollment in Cancer Clinical Trials. JAMA Netw Open [Internet]. American Medical Association; 2020 [cited 2020 Aug 2];3:e2010651. Available from: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2766577
Upadhaya S, Yu JX, Oliva C, Hooton M, Hodge J, Hubbard-Lucey VM. Impact of COVID-19 on oncology clinical trials. Nat Rev Drug Discov [Internet]. 2020 [cited 2020 Aug 2];19:376–7. Available from: http://www.nature.com/articles/d41573-020-00093-1
Waterhouse DM, Harvey RD, Hurley P, Levit LA, Kim ES, Klepin HD, et al. Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an American Society of Clinical Oncology Survey. JCO Oncol Pract [Internet]. American Society of Clinical Oncology; 2020 [cited 2020 Aug 2];16:417–21. Available from: https://ascopubs.org/doi/10.1200/OP.20.00275
Doherty GJ, Goksu M, de Paula BHR. Rethinking cancer clinical trials for COVID-19 and beyond. Nat Cancer [Internet]. Nature Publishing Group; 2020 [cited 2020 Aug 2];1:568–72. Available from: http://www.nature.com/articles/s43018-020-0083-x
Lowy: COVID-19 pandemic inspired new “shortcuts” in NCI clinical trials – The Cancer Letter [Internet]. [cited 2020 Aug 2]. Available from: https://cancerletter.com/articles/20200724_5/
Islami F, Sauer AG, Miller KD, Siegel RL, Fedewa SA, Jacobs EJ, et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin [Internet]. 2017;68:31–54. Available from: http://doi.wiley.com/10.3322/caac.21440
Li Y, Schoufour J, Wang DD, Dhana K, Pan A, Liu X, et al. Healthy lifestyle and life expectancy free of cancer, cardiovascular disease, and type 2 diabetes: prospective cohort study. BMJ [Internet]. British Medical Journal Publishing Group; 2020 [cited 2020 Jun 30];368. Available from: https://www.bmj.com/content/368/bmj.l6669
Vargas AJ, Schully SD, Villani J, Ganoza Caballero L, Murray DM. Assessment of Prevention Research Measuring Leading Risk Factors and Causes of Mortality and Disability Supported by the US National Institutes of Health. JAMA Netw open. 2019;2:e1914718.
Scott S. Annual Report to the Nation on the Status of Cancer , Part II : Progress Toward Healthy People 2020 Objectives for 4 Common Cancers. 2020;1–17.
Creamer MLR, Wang TW, Babb S, Cullen KA, Day H, Willis G, et al. Tobacco Product Use and Cessation Indicators Among Adults – United States, 2018. MMWR Morb Mortal Wkly Rep. 2019;68:1013–9.
Craig M. Hales, M.D., Margaret D. Carroll, M.S.P.H., Cheryl D. Fryar, M.S.P.H., and Cynthia L. Ogden PD. Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017–2018. NCHS Data Brief [Internet]. 2020;1–8. Available from: https://www.cdc.gov/nchs/data/databriefs/db360-h.pdf
AM W, IP C, RW H, PA P. Using Death Certificates to Explore Changes in Alcohol-Related Mortality in the United States, 1999 to 2017. Alcohol Clin Exp Res [Internet]. Alcohol Clin Exp Res; 2020 [cited 2020 Jun 30];44. Available from: https://pubmed.ncbi.nlm.nih.gov/31912524/
Correnti CM, Klein DJ, Elliott MN, Veledar E, Saraiya M, Chien AT, et al. Racial disparities in fifth-grade sun protection: Evidence from the Healthy Passages study. Pediatr Dermatol [Internet]. 2018 [cited 2019 Jul 7];35:588–96. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29962040
Elam-Evans LD, Yankey D, Singleton JA, Sterrett N, Markowitz LE, Williams CL, et al. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2019. MMWR Morb Mortal Wkly Rep [Internet]. 2020 [cited 2020 Aug 20];69:1109–16. Available from: http://www.cdc.gov/mmwr/volumes/69/wr/mm6933a1.htm?s_cid=mm6933a1_w
Barrow TM, Klett H, Toth R, Böhm J, Gigic B, Habermann N, et al. Smoking is associated with hypermethylation of the APC 1A promoter in colorectal cancer: the ColoCare Study. J Pathol [Internet]. 2017 [cited 2018 Mar 15];243:366–75. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28791728
Vaz M, Hwang SY, Kagiampakis I, Phallen J, Patil A, O’Hagan HM, et al. Chronic Cigarette Smoke-Induced Epigenomic Changes Precede Sensitization of Bronchial Epithelial Cells to Single-Step Transformation by KRAS Mutations. Cancer Cell [Internet]. 2017 [cited 2018 Mar 15];32:360-376.e6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28898697
CDC Vital Signs, November 2016. Cancer and tobacco use. CDC Vital Signs, November, 2016.
Yoshida K, Gowers KHC, Lee-Six H, Chandrasekharan DP, Coorens T, Maughan EF, et al. Tobacco smoking and somatic mutations in human bronchial epithelium. Nature [Internet]. Nature Publishing Group; 2020 [cited 2020 Jun 30];578:266–72. Available from: http://www.nature.com/articles/s41586-020-1961-1
Smoking Cessation: A Report of the Surgeon General. J Urol. 2020;
Tsai J, Homa DM, Gentzke AS, Mahoney M, Sharapova SR, Sosnoff CS, et al. Exposure to Secondhand Smoke Among Nonsmokers — United States, 1988–2014. MMWR Morb Mortal Wkly Rep [Internet]. 2018;67:1342–6. Available from: http://www.cdc.gov/mmwr/volumes/67/wr/mm6748a3.htm?s_cid=mm6748a3_w
Bonnie RJ, Stratton K, Kwan LY, editors. Public Health Implications of Raising the Minimum Age of Legal Access to Tobacco Products [Internet]. Washington, D.C.: National Academies Press; 2015 [cited 2019 May 21]. Available from: http://www.nap.edu/catalog/18997
Cancer Trends Progress Report National Cancer Institute, NIH, DHHS, Bethesda, MD, March 2020, https://progressreport.cancer.gov. [Internet]. [cited 2020 Jun 30]. Available from: https://progressreport.cancer.gov/
TW W, AS G, MR C, KA C, E H-H, MD S, et al. Tobacco Product Use and Associated Factors Among Middle and High School Students – United States, 2019. MMWR Surveill Summ [Internet]. MMWR Surveill Summ; 2019 [cited 2020 Jun 30];68. Available from: https://pubmed.ncbi.nlm.nih.gov/31805035/
WHC L, KY H, MP W, DYT C, KKW L, W X, et al. Effectiveness of a Brief Self-determination Theory-Based Smoking Cessation Intervention for Smokers at Emergency Departments in Hong Kong: A Randomized Clinical Trial. JAMA Intern Med [Internet]. JAMA Intern Med; 2019 [cited 2020 Jun 30];180. Available from: https://pubmed.ncbi.nlm.nih.gov/31790546/
E N-B, JE D, B HW, NA R, DJ O, DE L, et al. Treating Parents for Tobacco Use in the Pediatric Setting: The Clinical Effort Against Secondhand Smoke Exposure Cluster Randomized Clinical Trial. JAMA Pediatr [Internet]. JAMA Pediatr; 2019 [cited 2020 Jun 30];173. Available from: https://pubmed.ncbi.nlm.nih.gov/31403675/
Christensen CH, Rostron B, Cosgrove C, Altekruse SF, Hartman AM, Gibson JT, et al. Association of Cigarette, Cigar, and Pipe Use With Mortality Risk in the US Population. JAMA Intern Med [Internet]. American Medical Association; 2018 [cited 2018 May 4];178:469. Available from: http://archinte.jamanetwork.com/article.aspx?doi=10.1001/jamainternmed.2017.8625
Epidemic TE, Youth A. Surgeon General ’ s Advisory on E-cigarette Use Among Youth The E-cigarette Epidemic Among Youth E-cigarettes Come in Many Shapes and Sizes You Can Take Action. 2018;2–5.
Stratton K, Kwan LY, Eaton DL, Effects H, Delivery N, Health P, et al. Public Health Consequences of E-Cigarettes [Internet]. National Academies Press; 2018. Available from: https://www.nap.edu/catalog/24952
Gentzke AS, Creamer M, Cullen KA, Ambrose BK, Willis G. Vital Signs : Tobacco Product Use Among Middle and High School Students — United States , 2011 – 2018. 2019;68:2011–8.
Cullen KA, Gentzke AS, Sawdey MD, Chang JT, Anic GM, Wang TW, et al. e-Cigarette Use Among Youth in the United States, 2019. JAMA [Internet]. American Medical Association; 2019 [cited 2020 Jun 30];322:2095. Available from: https://jamanetwork.com/journals/jama/fullarticle/2755265
Barrington-Trimis JL, Yang Z, Schiff S, Unger J, Cruz TB, Urman R, et al. E-cigarette Product Characteristics and Subsequent Frequency of Cigarette Smoking. Pediatrics [Internet]. American Academy of Pediatrics; 2020 [cited 2020 Jun 30];145. Available from: https://pediatrics.aappublications.org/content/145/5/e20191652
Bhatta DN, Glantz SA. Association of E-Cigarette Use With Respiratory Disease Among Adults: A Longitudinal Analysis. Am J Prev Med [Internet]. Elsevier; 2020 [cited 2020 Jun 30];58:182–90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31859175
Caporale A, Langham MC, Guo W, Johncola A, Chatterjee S, Wehrli FW. Acute Effects of Electronic Cigarette Aerosol Inhalation on Vascular Function Detected at Quantitative MRI. Radiology [Internet]. Radiological Society of North America ; 2019 [cited 2020 Jun 30];293:97–106. Available from: http://pubs.rsna.org/doi/10.1148/radiol.2019190562
Bjurlin MA, Matulewicz RS, Roberts TR, Dearing BA, Schatz D, Sherman S, et al. Carcinogen Biomarkers in the Urine of Electronic Cigarette Users and Implications for the Development of Bladder Cancer: A Systematic Review. Eur Urol Oncol [Internet]. Elsevier; 2020 [cited 2020 Jun 30];0. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32192941
Chatham-Stephens K, Roguski K, Jang Y, Cho P, Jatlaoui TC, Kabbani S, et al. Characteristics of Hospitalized and Nonhospitalized Patients in a Nationwide Outbreak of E-cigarette, or Vaping, Product Use-Associated Lung Injury – United States, November 2019. MMWR Morb Mortal Wkly Rep. 2019;68:1076–80.
Adkins SH, Anderson KN, Goodman AB, Twentyman E, Danielson ML, Kimball A, et al. Demographics, Substance Use Behaviors, and Clinical Characteristics of Adolescents With e-Cigarette, or Vaping, Product Use–Associated Lung Injury (EVALI) in the United States in 2019. JAMA Pediatr [Internet]. 2020 [cited 2020 Jun 30];e200756. Available from: https://jamanetwork.com/journals/jamapediatrics/fullarticle/2766132
Ellington S, Salvatore PP, Ko J, Danielson M, Kim L, Cyrus A, et al. Update: Product, Substance-Use, and Demographic Characteristics of Hospitalized Patients in a Nationwide Outbreak of E-cigarette, or Vaping, Product Use–Associated Lung Injury — United States, August 2019–January 2020. MMWR Morb Mortal Wkly Rep [Internet]. 2020 [cited 2020 Jun 30];69:44–9. Available from: http://www.cdc.gov/mmwr/volumes/69/wr/mm6902e2.htm?s_cid=mm6902e2_w
Heinzerling A, Armatas C, Karmarkar E, Attfield K, Guo W, Wang Y, et al. Severe Lung Injury Associated With Use of e-Cigarette, or Vaping, Products—California, 2019. JAMA Intern Med [Internet]. American Medical Association; 2020 [cited 2020 Jul 10];180:861. Available from: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2762714
References 151-200
Navon L, Jones CM, Ghinai I, King BA, Briss PA, Hacker KA, et al. Risk Factors for E-Cigarette, or Vaping, Product Use-Associated Lung Injury (EVALI) Among Adults Who Use E-Cigarette, or Vaping, Products – Illinois, July-October 2019. MMWR Morb Mortal Wkly Rep [Internet]. 2019 [cited 2020 Jun 30];68:1034–9. Available from: http://www.cdc.gov/mmwr/volumes/68/wr/mm6845e1.htm?s_cid=mm6845e1_w
AACR Cancer Progress Report 2019.
U.S. Department of Health and Human Services. E-Cigarette Use Among Youth and Young Adults. A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promoti.
Vallone DM, Cuccia AF, Briggs J, Xiao H, Schillo BA, Hair EC. Electronic Cigarette and JUUL Use Among Adolescents and Young Adults. JAMA Pediatr [Internet]. American Medical Association; 2020 [cited 2020 Jun 30];174:277. Available from: https://jamanetwork.com/journals/jamapediatrics/fullarticle/2759022
Miech R, Johnston L, O’Malley PM, Bachman JG, Patrick ME. Trends in Adolescent Vaping, 2017–2019. N Engl J Med [Internet]. Massachusetts Medical Society; 2019 [cited 2020 Jun 30];381:1490–1. Available from: http://www.nejm.org/doi/10.1056/NEJMc1910739
Evans-Polce R, Veliz P, Boyd CJ, McCabe V V., McCabe SE. Trends in E-Cigarette, Cigarette, Cigar, and Smokeless Tobacco Use Among US Adolescent Cohorts, 2014–2018. Am J Public Health [Internet]. American Public Health Association; 2020 [cited 2020 Jun 30];110:163–5. Available from: https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2019.305421
Dai H. Exposure to Secondhand Aerosol From Electronic Cigarettes Among US Youth From 2015 to 2018. JAMA Pediatr [Internet]. American Medical Association; 2020 [cited 2020 Jun 30];174:298. Available from: https://jamanetwork.com/journals/jamapediatrics/fullarticle/2759424
Tattan-Birch H, Brown J, Shahab L, Jackson SE. Association of the US Outbreak of Vaping-Associated Lung Injury With Perceived Harm of e-Cigarettes Compared With Cigarettes. JAMA Netw Open [Internet]. American Medical Association; 2020 [cited 2020 Jun 30];3:e206981. Available from: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2767134
Initiative T. Spinning a new tobacco industry.
Mariosa D, Carreras-Torres R, Martin RM, Johansson M, Brennan P. Commentary: What can Mendelian randomization tell us about causes of cancer? Int J Epidemiol [Internet]. Oxford Academic; 2019 [cited 2020 Jul 1];48:816–21. Available from: https://academic.oup.com/ije/article/48/3/816/5539268
Lauby‑secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K. Body Fatness and Cancer — Viewpoint of the IARC Working Group. 2016;8.
Body fatness and weight gain and the risk of cancer. World Cancer Res Fund/American Inst Cancer Res Contin Updat Proj Expert Rep 2018 Body fatness Weight gain risk cancer Available dietandcancerreport.org. 2018;
World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project Expert Report 2018. Physical activity and the risk of cancer. Available at http://www.dietandcancerreport.org
Moore SC, Lee I, Weiderpass E, Campbell PT, Sampson JN, Kitahara CM, et al. Association of Leisure-Time Physical Activity With Risk of 26 Types of Cancer in 1.44 Million Adults. 2016;20850:816–25.
Patel A V., Friedenreich CM, Moore SC, Hayes SC, Silver JK, Campbell KL, et al. American College of Sports Medicine Roundtable Report on Physical Activity, Sedentary Behavior, and Cancer Prevention and Control. Med Sci Sports Exerc. 2019;51:2391–402.
Matthews CE, Moore SC, Arem H, Cook MB, Trabert B, Håkansson N, et al. Amount and Intensity of Leisure-Time Physical Activity and Lower Cancer Risk. J Clin Oncol. 2019;JCO.19.02407.
Piercy KL, Troiano RP, Ballard RM, Carlson SA, Fulton JE, Galuska DA, et al. The Physical Activity Guidelines for Americans. JAMA [Internet]. American Medical Association; 2018 [cited 2019 Jun 19];320:2020. Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2018.14854
Ward ZJ, Bleich SN, Cradock AL, Barrett JL, Giles CM, Flax C, et al. Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity. N Engl J Med [Internet]. Massachusetts Medical Society; 2019 [cited 2020 Jul 1];381:2440–50. Available from: http://www.nejm.org/doi/10.1056/NEJMsa1909301
Geserick M, Vogel M, Gausche R, Lipek T, Spielau U, Keller E, et al. Acceleration of BMI in Early Childhood and Risk of Sustained Obesity. N Engl J Med [Internet]. Massachusetts Medical Society; 2018 [cited 2019 May 28];379:1303–12. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1803527
Levi Z, Rottenberg Y, Twig G, Katz L, Leiba A, Derazne E, et al. Adolescent overweight and obesity and the risk for pancreatic cancer among men and women: a nationwide study of 1.79 million Israeli adolescents. Cancer [Internet]. John Wiley & Sons, Ltd; 2019 [cited 2019 May 28];125:118–26. Available from: http://doi.wiley.com/10.1002/cncr.31764
Ward ZJ, Long MW, Resch SC, Giles CM, Cradock AL, Gortmaker SL, et al. Simulation of Growth Trajectories of Childhood Obesity into Adulthood. N Engl J Med [Internet]. 2017;377:2145–53. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1703860
CDC 2020. Prevalence of Obesity * and Severe Obesity † Among Persons Aged 2 – 19 Years — National Health and Nutrition Examination Survey ,. Morb Mortal Wkly Rep. 2020;69:4193.
Koroukian SM, Dong W, Berger NA. Changes in Age Distribution of Obesity-Associated Cancers. JAMA Netw open. 2019;2:e199261.
Sung H, Siegel RL, Rosenberg PS, Jemal A. Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry. Lancet Public Heal [Internet]. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license; 2019;0:1–11. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2468266718302676
Teras LR, Patel A V, Wang M, Yaun S-S, Anderson K, Brathwaite R, et al. Sustained Weight Loss and Risk of Breast Cancer in Women 50 Years and Older: A Pooled Analysis of Prospective Data. JNCI J Natl Cancer Inst [Internet]. 2019 [cited 2020 Jul 1]; Available from: https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djz226/5675519
Rock CL, Thomson C, Gansler T, Gapstur SM, McCullough ML, Patel A V., et al. American Cancer Society guideline for diet and physical activity for cancer prevention. CA Cancer J Clin [Internet]. American Cancer Society; 2020 [cited 2020 Jul 3];caac.21591. Available from: https://onlinelibrary.wiley.com/doi/abs/10.3322/caac.21591
Afshin A, Sur PJ, Fay KA, Cornaby L, Ferrara G, Salama JS, et al. Health effects of dietary risks in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet [Internet]. 2019;6736. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673619300418
Agriculture USD of H and HS and USD of. 2015 – 2020 Dietary Guidelines for Americans. 2015 – 2020 Diet Guidel Am (8th Ed. 2015;18.
Daepp MIG, Gortmaker SL, Wang YC, Long MW, Kenney EL. WIC Food Package Changes: Trends in Childhood Obesity Prevalence. Pediatrics [Internet]. 2019 [cited 2019 Jun 19];143:e20182841. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30936251
Pan L, Blanck HM, Park S, Galuska DA, Freedman DS, Potter A, et al. State-Specific Prevalence of Obesity Among Children Aged 2-4 Years Enrolled in the Special Supplemental Nutrition Program for Women, Infants, and Children – United States, 2010-2016. MMWR Morb Mortal Wkly Rep. 2019;68:1057–61.
FDA. What’s New With the Nutrition Facts Label? 2020;41–6.
Daley AJ, McGee E, Bayliss S, Coombe A, Parretti HM. Effects of physical activity calorie equivalent food labelling to reduce food selection and consumption: systematic review and meta-analysis of randomised controlled studies. J Epidemiol Community Heal [Internet]. BMJ Publishing Group Ltd; 2020 [cited 2020 Jul 1];74:269–75. Available from: https://jech.bmj.com/content/74/3/269
American Cancer Society. Cancer Prevention & Early Detection Facts & Figures 2017-2018.
Lee MM, Falbe J, Schillinger D, Basu S, McCulloch CE, Madsen KA. Sugar-Sweetened Beverage Consumption 3 Years After the Berkeley, California, Sugar-Sweetened Beverage Tax. Am J Public Health. 2019;109:637–9.
Roberto CA, Lawman HG, Levasseur MT, Mitra N, Peterhans A, Herring B, et al. Association of a Beverage Tax on Sugar-Sweetened and Artificially Sweetened Beverages with Changes in Beverage Prices and Sales at Chain Retailers in a Large Urban Setting. JAMA – J Am Med Assoc. 2019;321:1799–810.
AH G, BB L, D T, H A. Designing Better Sugary Drink Taxes. Science [Internet]. Science; 2019 [cited 2020 Jul 1];365. Available from: https://pubmed.ncbi.nlm.nih.gov/31488678/
Y L, D M, S S, J L, PE W, M M, et al. Health Impact and Cost-Effectiveness of Volume, Tiered, and Absolute Sugar Content SugarSweetened Beverage Tax Policies in the United States: A Microsimulation Study. Circulation [Internet]. Circulation; 2020 [cited 2020 Jul 1]; Available from: https://pubmed.ncbi.nlm.nih.gov/32564614/
Gilchrist SC, Howard VJ, Akinyemiju T, Judd SE, Cushman M, Hooker SP, et al. Association of Sedentary Behavior With Cancer Mortality in Middle-aged and Older US Adults. JAMA Oncol [Internet]. 2020 [cited 2020 Jul 1]; Available from: https://jamanetwork.com/journals/jamaoncology/fullarticle/2767093
Pedisic Z, Shrestha N, Kovalchik S, Stamatakis E, Liangruenrom N, Grgic J, et al. Is running associated with a lower risk of all-cause, cardiovascular and cancer mortality, and is the more the better? A systematic review and meta-analysis. Br J Sports Med [Internet]. BMJ Publishing Group Ltd and British Association of Sport and Exercise Medicine; 2019 [cited 2020 Jul 1]; Available from: https://bjsm.bmj.com/content/early/2019/09/25/bjsports-2018-100493
National Physical Activity Plan Alliance. The 2018 United States Report Card on Physical Activity for Children and Youth. Washington, DC: National Physical Activity Plan Alliance, 2018. 2001;8:33–42.
Saint-Maurice PF, Troiano RP, Bassett DR, Graubard BI, Carlson SA, Shiroma EJ, et al. Association of Daily Step Count and Step Intensity With Mortality Among US Adults. JAMA [Internet]. American Medical Association; 2020 [cited 2020 Jul 1];323:1151. Available from: https://jamanetwork.com/journals/jama/fullarticle/2763292
Alcoholic drinks and the risk of cancer. This part World Cancer Res Fund/American Inst Cancer Res Contin Updat Proj Expert Rep 2018 Alcohol Drink risk cancer Available http://www.dietandcancerreport.org. 2018;
White AJ, DeRoo LA, Weinberg CR, Sandler DP. Lifetime Alcohol Intake, Binge Drinking Behaviors, and Breast Cancer Risk. Am J Epidemiol [Internet]. Oxford University Press; 2017 [cited 2018 May 7];186:541–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28486582
References 201-250
LoConte NK, Brewster AM, Kaur JS, Merrill JK, Alberg AJ. Alcohol and Cancer: A Statement of the American Society of Clinical Oncology. J Clin Oncol [Internet]. 2018 [cited 2018 May 3];36:83–93. Available from: http://ascopubs.org/doi/10.1200/JCO.2017.76.1155
Hydes TJ, Burton R, Inskip H, Bellis MA, Sheron N. A comparison of gender-linked population cancer risks between alcohol and tobacco: how many cigarettes are there in a bottle of wine? BMC Public Health [Internet]. BioMed Central; 2019 [cited 2019 May 10];19:316. Available from: https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-019-6576-9
World Health Organization., World Health Organization, World Health Organization. Management of Substance Abuse Team. Global status report on alcohol and health 2018.
LoConte NK, Brewster AM, Kaur JS, Merrill JK, Alberg AJ. Alcohol and cancer: A statement of the American society of clinical oncology. J Clin Oncol. 2018;36:83–93.
States U, Kanny D, Naimi TS, Liu Y, Brewer RD. Trends in Total Binge Drinks per Adult Who Reported Binge Drinking —. 2020;69:30–4.
Han BH, Moore AA, Ferris R, Palamar JJ. Binge Drinking Among Older Adults in the United States, 2015 to 2017. J Am Geriatr Soc [Internet]. John Wiley & Sons, Ltd; 2019 [cited 2020 Mar 16];67:2139–44. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/jgs.16071
White AM, Castle IJP, Hingson RW, Powell PA. Using Death Certificates to Explore Changes in Alcohol-Related Mortality in the United States, 1999 to 2017. Alcohol Clin Exp Res. 2020;44:178–87.
S S, MS S, AF B, EA H, DR W, Y C, et al. Trends in Alcohol-Induced Deaths in the United States, 2000-2016. JAMA Netw open [Internet]. JAMA Netw Open; 2020 [cited 2020 Jul 1];3. Available from: https://pubmed.ncbi.nlm.nih.gov/32083687/
Esser MB, Sherk A, Liu Y, Naimi TS, Stockwell T, Stahre M, et al. Deaths and Years of Potential Life Lost From Excessive Alcohol Use — United States, 2011–2015. MMWR Morb Mortal Wkly Rep [Internet]. 2020 [cited 2020 Jul 30];69:981–7. Available from: http://www.cdc.gov/mmwr/volumes/69/wr/mm6930a1.htm?s_cid=mm6930a1_w
McKnight-Eily LR, Okoro CA, Turay K, Acero C, Hungerford D. Screening for Alcohol Use and Brief Counseling of Adults – 13 States and the District of Columbia, 2017. MMWR Morb Mortal Wkly Rep. 2020;69:265–70.
GBD 2016 Alcohol and Drug Use Collaborators L, Charlson F, Ferrari A, Santomauro D, Erskine H, Mantilla-Herrara A, et al. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. The lancet Psychiatry [Internet]. Elsevier; 2018 [cited 2019 May 10];5:987–1012. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30392731
Zhao J, Stockwell T, Vallance K, Hobin E. The Effects of Alcohol Warning Labels on Population Alcohol Consumption: An Interrupted Time Series Analysis of Alcohol Sales in Yukon, Canada. J Stud Alcohol Drugs [Internet]. Rutgers University; 2020 [cited 2020 Jul 1];81:225–37. Available from: https://www.jsad.com/doi/10.15288/jsad.2020.81.225
Hobin E, Weerasinghe A, Vallance K, Hammond D, McGavock J, Greenfield TK, et al. Testing Alcohol Labels as a Tool to Communicate Cancer Risk to Drinkers: A Real-World Quasi-Experimental Study. J Stud Alcohol Drugs [Internet]. Rutgers University; 2020 [cited 2020 Jul 1];81:249–61. Available from: https://www.jsad.com/doi/10.15288/jsad.2020.81.249
Islami F, Sauer AG, Miller KD, Fedewa SA, Minihan AK, Geller AC, et al. Cutaneous melanomas attributable to ultraviolet radiation exposure by state. Int J Cancer [Internet]. John Wiley & Sons, Ltd; 2020 [cited 2020 Jul 1];ijc.32921. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.32921
Dennis LK, Vanbeek MJ, Beane Freeman LE, Smith BJ, Dawson D V, Coughlin JA. Sunburns and risk of cutaneous melanoma: does age matter? A comprehensive meta-analysis. Ann Epidemiol [Internet]. NIH Public Access; 2008 [cited 2019 Jul 10];18:614–27. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18652979
AP T, FJ G. Melanoma Incidence Among Non-Hispanic Whites in All 50 US States From 2001 Through 2015. J Natl Cancer Inst [Internet]. J Natl Cancer Inst; 2020 [cited 2020 Jul 1];112. Available from: https://pubmed.ncbi.nlm.nih.gov/31346623/
Guy GP, Watson M, Seidenberg AB, Hartman AM, Holman DM, Perna F. Trends in indoor tanning and its association with sunburn among US adults. J Am Acad Dermatol [Internet]. 2017 [cited 2018 Jun 18];76:1191–3. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0190962217300877
Guy GP, Berkowitz Z, Everett Jones S, Watson M, Richardson LC. Prevalence of Indoor Tanning and Association With Sunburn Among Youth in the United States. JAMA dermatology [Internet]. 2017 [cited 2018 Jun 18];153:387–90. Available from: http://archderm.jamanetwork.com/article.aspx?doi=10.1001/jamadermatol.2016.6273
Paulson KG, Gupta D, Kim TS, Veatch JR, Byrd DR, Bhatia S, et al. Age-Specific Incidence of Melanoma in the United States. JAMA Dermatology [Internet]. American Medical Association; 2020 [cited 2020 Jul 1];156:57. Available from: https://jamanetwork.com/journals/jamadermatology/fullarticle/2754716
Goding Sauer A, Siegel RL, Jemal A, Fedewa SA. Current Prevalence of Major Cancer Risk Factors and Screening Test Use in the United States: Disparities by Education and Race/Ethnicity. Cancer Epidemiol Biomarkers Prev. 2019;28:629–42.
IPSOS Public Affairs e-Nation survey conducted May 9, 2019 on behalf of The Blue Cross Blue Shield Association. 2017;32:81–4. Available from: https://bcbs.com/the-health-of-america
Brinker TJ, Faria BL, de Faria OM, Klode J, Schadendorf D, Utikal JS, et al. Effect of a Face-Aging Mobile App–Based Intervention on Skin Cancer Protection Behavior in Secondary Schools in Brazil. JAMA Dermatology [Internet]. 2020 [cited 2020 Jul 1]; Available from: https://jamanetwork.com/journals/jamadermatology/fullarticle/2764794
Gordon LG, Rodriguez-Acevedo AJ, Køster B, Guy GP, Sinclair C, Van Deventer E, et al. Association of Indoor Tanning Regulations With Health and Economic Outcomes in North America and Europe. JAMA Dermatology [Internet]. American Medical Association; 2020 [cited 2020 Jul 1];156:401. Available from: https://jamanetwork.com/journals/jamadermatology/fullarticle/2760693
de Martel C, Georges D, Bray F, Ferlay J, Clifford GM, Martel C de, et al. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Heal [Internet]. International Agency for Research on Cancer; 2020 [cited 2020 Jul 1];8:e180–90. Available from: https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(19)30488-7/fulltext
Hong CY, Sinn DH, Kang D, Paik SW, Guallar E, Cho J, et al. Incidence of extrahepatic cancers among individuals with chronic hepatitis B or C virus infection: A nationwide cohort study. J Viral Hepat [Internet]. John Wiley & Sons, Ltd; 2020 [cited 2020 Aug 6];jvh.13304. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/jvh.13304
Blythe Ryerson A, Schillie S, Barker LK, Kupronis BA, Wester C. Vital signs: Newly reported acute and chronic hepatitis C cases — United States, 2009–2018. Morb Mortal Wkly Rep. 2020;69:399–404.
Cleary M. CDC Recommendations for Hepatitis C Screening among Adults. J Chem Inf Model. 2019;53:1689–99.
DK O, KW D, AH K, MJ B, M C, AB C, et al. Screening for Hepatitis C Virus Infection in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement. JAMA [Internet]. JAMA; 2020 [cited 2020 Jul 1]; Available from: https://pubmed.ncbi.nlm.nih.gov/32119076/
Senkomago V, Henley SJ, Thomas CC, Mix JM, Markowitz LE, Saraiya M. Human Papillomavirus – Attributable Cancers — United States , 2012 – 2016. 2019;68:2012–6.
AK C, BI G, T B, W X, RKL P, L K, et al. Prevalence of Oral HPV Infection in Unvaccinated Men and Women in the United States, 2009-2016. JAMA [Internet]. JAMA; 2019 [cited 2020 Jul 1];322. Available from: https://pubmed.ncbi.nlm.nih.gov/31503300/
Boersma P, Black LI. Human Papillomavirus Vaccination Among Adults Aged 18-26, 2013-2018. NCHS Data Brief. 2020;1–8.
Hall MT, Simms KT, Lew J-B, Smith MA, Brotherton JM, Saville M, et al. The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Public Heal [Internet]. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC-BY-NC-ND 4.0 license; 2018;2667:1–9. Available from: https://linkinghub.elsevier.com/retrieve/pii/S246826671830183X
Arbyn M, Weiderpass E, Bruni L, Sanjosé S de, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Heal [Internet]. Elsevier; 2020 [cited 2020 Jul 1];8:e191–203. Available from: https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(19)30482-6/fulltext
Simms KT, Steinberg J, Caruana M, Smith MA, Lew J-B, Soerjomataram I, et al. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study. Lancet Oncol [Internet]. Elsevier; 2019 [cited 2019 May 1];20:394–407. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30795950
Van Dyne EA, Henley SJ, Saraiya M, Thomas CC, Markowitz LE, Benard VB. Trends in Human Papillomavirus–Associated Cancers — United States, 1999–2015. MMWR Morb Mortal Wkly Rep [Internet]. 2018;67:918–24. Available from: http://www.cdc.gov/mmwr/volumes/67/wr/mm6733a2.htm?s_cid=mm6733a2_w
Deshmukh AA, Suk R, Shiels MS, Sonawane K, Nyitray AG, Liu Y, et al. Recent Trends in Squamous Cell Carcinoma of the Anus Incidence and Mortality in the United States, 2001–2015. JNCI J Natl Cancer Inst [Internet]. 2019 [cited 2020 Jul 1]; Available from: https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djz219/5622917
Rodriguez AM, Zeybek B, Vaughn M, Westra J, Kaul S, Montealegre JR, et al. Comparison of the long‐term impact and clinical outcomes of fewer doses and standard doses of human papillomavirus vaccine in the United States: A database study. Cancer [Internet]. John Wiley & Sons, Ltd; 2020 [cited 2020 Jul 1];126:1656–67. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.32700
Brewer NT, Hall ME, Malo TL, Gilkey MB, Quinn B, Lathren C. Announcements Versus Conversations to Improve HPV Vaccination Coverage: A Randomized Trial. Pediatrics. 2016;
Kempe A, O’Leary ST, Markowitz LE, Crane LA, Hurley LP, Brtnikova M, et al. HPV Vaccine Delivery Practices by Primary Care Physicians. Pediatrics [Internet]. American Academy of Pediatrics; 2019 [cited 2020 Jul 1];144. Available from: https://pediatrics.aappublications.org/content/144/4/e20191475
Ko JS, Goldbeck CS, Baughan EB, Klausner JD. Association Between Human Papillomavirus Vaccination School-Entry Requirements and Vaccination Initiation. JAMA Pediatr [Internet]. 2020 [cited 2020 Jul 1]; Available from: https://jamanetwork.com/journals/jamapediatrics/fullarticle/2767275
Palmer JR, Viscidi E, Troester MA, Hong C-C, Schedin P, Bethea TN, et al. Parity, lactation, and breast cancer subtypes in African American women: results from the AMBER Consortium. J Natl Cancer Inst [Internet]. 2014 [cited 2019 Jun 19];106. Available from: https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/dju237
Islami F, Liu Y, Jemal A, Zhou J, Weiderpass E, Colditz G, et al. Breastfeeding and breast cancer risk by receptor status–a systematic review and meta-analysis. Ann Oncol Off J Eur Soc Med Oncol [Internet]. 2015 [cited 2019 Jun 19];26:2398–407. Available from: https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdv379
A B, N S, BA R, SS T, SJ J, HA R, et al. Association Between Breastfeeding and Ovarian Cancer Risk. JAMA Oncol [Internet]. JAMA Oncol; 2020 [cited 2020 Jul 1];6. Available from: https://pubmed.ncbi.nlm.nih.gov/32239218/
Moorman PG, Alberg AJ, Bandera E V, Barnholtz-Sloan J, Bondy M, Cote ML, et al. Reproductive factors and ovarian cancer risk in African-American women. Ann Epidemiol [Internet]. NIH Public Access; 2016 [cited 2020 Jul 28];26:654–62. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27528178
Beauregard JL, Hamner HC, Chen J, Avila-Rodriguez W, Elam-Evans LD, Perrine CG. Racial Disparities in Breastfeeding Initiation and Duration Among U.S. Infants Born in 2015. Morb Mortal Wkly Rep [Internet]. Centers for Disease Control and Prevention; 2019 [cited 2020 Jul 1];68:745. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6715261/
Chlebowski RT, Anderson G, Pettinger M, Lane D, Langer RD, Gilligan MA, et al. Estrogen Plus Progestin and Breast Cancer Detection by Means of Mammography and Breast Biopsy. Arch Intern Med [Internet]. 2008 [cited 2019 Jun 19];168:370. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18299491
Chlebowski RT, Anderson GL, Aragaki AK, Manson JE, Stefanick ML, Pan K, et al. Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials. JAMA [Internet]. American Medical Association; 2020 [cited 2020 Aug 2];324:369. Available from: https://jamanetwork.com/journals/jama/fullarticle/2768806
References 251-300
Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, et al. Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women. N Engl J Med [Internet]. 2009 [cited 2019 Jun 19];360:573–87. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa0807684
Ellingjord-Dale M, Vos L, Tretli S, Hofvind S, Dos-Santos-Silva I, Ursin G. Parity, hormones and breast cancer subtypes – results from a large nested case-control study in a national screening program. Breast Cancer Res [Internet]. 2017 [cited 2019 Jun 19];19:10. Available from: http://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-016-0798-x
Rosenberg L, Bethea TN, Viscidi E, Hong C-C, Troester MA, Bandera E V, et al. Postmenopausal Female Hormone Use and Estrogen Receptor-Positive and -Negative Breast Cancer in African American Women. J Natl Cancer Inst [Internet]. 2016 [cited 2019 Jun 19];108:djv361. Available from: https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djv361
Loomis D, Grosse Y, Lauby-Secretan B, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, et al. The carcinogenicity of outdoor air pollution. Lancet Oncol [Internet]. 2013 [cited 2019 Jun 19];14:1262–3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25035875
The American Lung Association “State of the Air® 2020.” 2020;
Fortner RT, Poole EM, Wentzensen NA, Trabert B, White E, Arslan AA, et al. Ovarian cancer risk factors by tumor aggressiveness: An analysis from the Ovarian Cancer Cohort Consortium. Int J Cancer [Internet]. John Wiley & Sons, Ltd; 2019 [cited 2020 Jul 1];145:58–69. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.32075
Yarmolinsky J, Relton CL, Lophatananon A, Muir K, Menon U, Gentry-Maharaj A, et al. Appraising the role of previously reported risk factors in epithelial ovarian cancer risk: A Mendelian randomization analysis. Minelli C, editor. PLOS Med [Internet]. Public Library of Science; 2019 [cited 2020 Jul 1];16:e1002893. Available from: https://dx.plos.org/10.1371/journal.pmed.1002893
H K, T H, M S, L L, Y C, JA N, et al. Physical Activity and Colorectal Cancer Prognosis According to Tumor-Infiltrating T Cells. JNCI cancer Spectr [Internet]. JNCI Cancer Spectr; 2018 [cited 2020 Jul 1];2. Available from: https://pubmed.ncbi.nlm.nih.gov/31276098/
de la Iglesia J V., Slebos RJC, Martin-Gomez L, Wang X, Teer JK, Tan AC, et al. Effects of tobacco smoking on the tumor immune microenvironment in head and neck squamous cell carcinoma. Clin Cancer Res. 2020;26:1474–85.
Chida Y, Hamer M, Wardle J, Steptoe A. Do stress-related psychosocial factors contribute to cancer incidence and survival? Nat Clin Pract Oncol [Internet]. 2008 [cited 2019 Dec 16];5:466–75. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18493231
Roberts AL, Huang T, Koenen KC, Kim Y, Kubzansky LD, Tworoger SS. Posttraumatic stress disorder (PTSD) is associated with increased risk of ovarian cancer: a prospective and retrospective longitudinal cohort study. Cancer Res [Internet]. American Association for Cancer Research; 2019 [cited 2020 Jul 1]; Available from: https://cancerres.aacrjournals.org/content/early/2019/09/04/0008-5472.CAN-19-1222
Moreno-Smith M, Lutgendorf SK, Sood AK. Impact of stress on cancer metastasis. Futur Oncol [Internet]. Future Medicine Ltd London, UK ; 2010 [cited 2020 Jul 1];6:1863–81. Available from: https://www.futuremedicine.com/doi/10.2217/fon.10.142
CB C-E, R L-C, AN A-A, GN A-P. Neuroendocrine Regulation of Tumor-Associated Immune Cells. Front Oncol [Internet]. Front Oncol; 2019 [cited 2020 Jul 1];9. Available from: https://pubmed.ncbi.nlm.nih.gov/31737559/
Antoni MH, Dhabhar FS. The impact of psychosocial stress and stress management on immune responses in patients with cancer. Cancer [Internet]. John Wiley & Sons, Ltd; 2019 [cited 2020 Jul 1];125:1417–31. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.31943
Xing CY, Doose M, Qin B, Lin Y, Plascak JJ, Omene C, et al. Prediagnostic Allostatic Load as a Predictor of Poorly Differentiated and Larger Sized Breast Cancers among Black Women in the Women’s Circle of Health Follow-Up Study. Cancer Epidemiol Biomarkers Prev [Internet]. 2020 [cited 2020 Jan 22];29:216–24. Available from: http://cebp.aacrjournals.org/lookup/doi/10.1158/1055-9965.EPI-19-0712
Zeleznik OA, Eliassen AH, Kraft P, Poole EM, Rosner BA, Jeanfavre S, et al. A prospective analysis of circulating plasma metabolites associated with ovarian cancer risk. Cancer Res [Internet]. American Association for Cancer Research; 2020 [cited 2020 Jul 1]; Available from: https://cancerres.aacrjournals.org/content/early/2020/01/22/0008-5472.CAN-19-2567
Zhao H, Shen J, Moore SC, Ye Y, Wu X, Esteva FJ, et al. Breast cancer risk in relation to plasma metabolites among Hispanic and African American women. Breast Cancer Res Treat [Internet]. Springer; 2019 [cited 2020 Jul 1];176:687–96. Available from: http://link.springer.com/10.1007/s10549-019-05165-4
X S, YB X, N R, D Y, HL L, G Y, et al. Prospective Study of Blood Metabolites Associated With Colorectal Cancer Risk. Int J cancer [Internet]. Int J Cancer; 2018 [cited 2020 Jul 1];143. Available from: https://pubmed.ncbi.nlm.nih.gov/29479691/
Zeleznik OA, Clish CB, Kraft P, Avila-Pacheco J, Eliassen AH, Tworoger SS. Circulating Lysophosphatidylcholines, Phosphatidylcholines, Ceramides, and Sphingomyelins and Ovarian Cancer Risk: A 23-Year Prospective Study. J Natl Cancer Inst [Internet]. J Natl Cancer Inst; 2020 [cited 2020 Jul 28];112:628–36. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31593240
Mayers JR, Wu C, Clish CB, Kraft P, Torrence ME, Fiske BP, et al. Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat Med [Internet]. Nat Med; 2014 [cited 2020 Jul 28];20:1193–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25261994
Dickerman BA, Ebot EM, Healy BC, Wilson KM, Eliassen AH, Ascherio A, et al. A Metabolomics Analysis of Adiposity and Advanced Prostate Cancer Risk in the Health Professionals Follow-Up Study. Metabolites [Internet]. Metabolites; 2020 [cited 2020 Jul 28];10. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32164144
Rodriguez-Ruiz A, Lång K, Gubern-Merida A, Broeders M, Gennaro G, Clauser P, et al. Stand-Alone Artificial Intelligence for Breast Cancer Detection in Mammography: Comparison With 101 Radiologists. JNCI J Natl Cancer Inst [Internet]. Oxford Academic; 2019 [cited 2020 Jul 1];111:916–22. Available from: https://academic.oup.com/jnci/article/111/9/916/5307077
McKinney SM, Sieniek M, Godbole V, Godwin J, Antropova N, Ashrafian H, et al. International evaluation of an AI system for breast cancer screening. Nature [Internet]. Nature Publishing Group; 2020 [cited 2020 Jul 1];577:89–94. Available from: http://www.nature.com/articles/s41586-019-1799-6
Schaffter T, Buist DSM, Lee CI, Nikulin Y, Ribli D, Guan Y, et al. Evaluation of Combined Artificial Intelligence and Radiologist Assessment to Interpret Screening Mammograms. JAMA Netw Open [Internet]. American Medical Association; 2020 [cited 2020 Jul 1];3:e200265. Available from: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2761795
Lennon AM, Buchanan AH, Kinde I, Warren A, Honushefsky A, Cohain AT, et al. Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science (80- ) [Internet]. American Association for the Advancement of Science; 2020 [cited 2020 Jul 1]; Available from: https://science.sciencemag.org/content/early/2020/04/27/science.abb9601
Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden M V., Liu MC, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31:745–59.
SW D, L T, AM Y, PB D, RA S, H J, et al. Mammography Screening Reduces Rates of Advanced and Fatal Breast Cancers: Results in 549,091 Women. Cancer [Internet]. Cancer; 2020 [cited 2020 Jul 1];126. Available from: https://pubmed.ncbi.nlm.nih.gov/32390151/
Fontham ETH, Wolf AMD, Church TR, Etzioni R, Flowers CR, Herzig A, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin [Internet]. American Cancer Society; 2020 [cited 2020 Aug 3];caac.21628. Available from: https://onlinelibrary.wiley.com/doi/abs/10.3322/caac.21628
Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, et al. Mammographic Density and the Risk and Detection of Breast Cancer. N Engl J Med [Internet]. Massachusetts Medical Society ; 2007 [cited 2020 Jul 1];356:227–36. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa062790
Kurian AW, Bernhisel R, Larson K, Caswell-Jin JL, Shadyab AH, Ochs-Balcom H, et al. Prevalence of Pathogenic Variants in Cancer Susceptibility Genes among Women with Postmenopausal Breast Cancer. JAMA – J Am Med Assoc. 2020;323:995–7.
Yadav S, Hu C, Hart SN, Boddicker N, Polley EC, Na J, et al. Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer. J Clin Oncol. 2020;JCO.19.02190.
H Z, TU A, J L, D B, J B, G Q, et al. Genome-wide Association Study Identifies 32 Novel Breast Cancer Susceptibility Loci From Overall and Subtype-Specific Analyses. Nat Genet [Internet]. Nat Genet; 2020 [cited 2020 Jul 1];52. Available from: https://pubmed.ncbi.nlm.nih.gov/32424353/
TA O, DM G, F A, D A, K A, J A, et al. Identification of Nine New Susceptibility Loci for Endometrial Cancer. Nat Commun [Internet]. Nat Commun; 2018 [cited 2020 Jul 1];9. Available from: https://pubmed.ncbi.nlm.nih.gov/30093612/
Nelson HD, Pappas M, Cantor A, Haney E, Holmes R. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA- Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA – J Am Med Assoc. 2019;322:666–85.
Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, et al. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J Clin Oncol [Internet]. American Society of Clinical Oncology; 2020 [cited 2020 Aug 3];JCO2000046. Available from: https://ascopubs.org/doi/10.1200/JCO.20.00046
JR P, EC P, C H, EM J, C H, SN H, et al. Contribution of Germline Predisposition Gene Mutations to Breast Cancer Risk in African American Women. J Natl Cancer Inst [Internet]. J Natl Cancer Inst; 2020 [cited 2020 Jul 1]; Available from: https://pubmed.ncbi.nlm.nih.gov/32427313/
L N. US Preventive Services Task Force Breast Cancer Recommendation Statement on Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer. JAMA Surg [Internet]. JAMA Surg; 2019 [cited 2020 Jul 1];154. Available from: https://pubmed.ncbi.nlm.nih.gov/31429868/
Spira A, Yurgelun MB, Alexandrov L, Rao A, Bejar R, Polyak K, et al. Precancer Atlas to Drive Precision Prevention Trials. Cancer Res. United States; 2017;77:1510–41.
Rebbeck TR, Burns-White K, Chan AT, Emmons K, Freedman M, Hunter DJ, et al. Precision Prevention and Early Detection of Cancer: Fundamental Principles. Cancer Discov. United States; 2018;8:803–11.
Aldrich MC, Mercaldo SF, Sandler KL, Blot WJ, Grogan EL, Blume JD. Evaluation of USPSTF Lung Cancer Screening Guidelines Among African American Adult Smokers. JAMA Oncol [Internet]. 2019 [cited 2020 Jan 27];5:1318. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31246249
Bakker MF, de Lange S V., Pijnappel RM, Mann RM, Peeters PHM, Monninkhof EM, et al. Supplemental MRI Screening for Women with Extremely Dense Breast Tissue. N Engl J Med [Internet]. Massachusetts Medical Society; 2019 [cited 2020 Jul 1];381:2091–102. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1903986
Comstock CE, Gatsonis C, Newstead GM, Snyder BS, Gareen IF, Bergin JT, et al. Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women With Dense Breasts Undergoing Screening. JAMA [Internet]. American Medical Association; 2020 [cited 2020 Jul 1];323:746. Available from: https://jamanetwork.com/journals/jama/fullarticle/2761645
Turcotte LM, Neglia JP, Reulen RC, Ronckers CM, Leeuwen FE van, Morton LM, et al. Risk, Risk Factors, and Surveillance of Subsequent Malignant Neoplasms in Survivors of Childhood Cancer: A Review. J Clin Oncol [Internet]. American Society of Clinical Oncology; 2018 [cited 2020 Jul 1];36:2145. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075849/#!po=61.7647
Armstrong GT, Chen Y, Yasui Y, Leisenring W, Gibson TM, Mertens AC, et al. Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer. N Engl J Med [Internet]. NIH Public Access; 2016 [cited 2019 Jun 20];374:833–42. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26761625
References 301-350
White A, Thompson TD, White MC, Sabatino SA, de Moor J, Doria-Rose P V., et al. Cancer Screening Test Use — United States, 2015. MMWR Morb Mortal Wkly Rep [Internet]. 2017 [cited 2019 Jun 20];66:201–6. Available from: http://www.cdc.gov/mmwr/volumes/66/wr/mm6608a1.htm
Joseph DA, King JB, Dowling NF, Thomas CC, Richardson LC. Vital Signs : Colorectal Cancer Screening Test Use — United States, 2018. MMWR Morb Mortal Wkly Rep [Internet]. 2020 [cited 2020 Jul 1];69:253–9. Available from: http://www.cdc.gov/mmwr/volumes/69/wr/mm6910a1.htm?s_cid=mm6910a1_w
No WV, Richards TB, Soman A, Thomas CC, Vanfrank B, Henley SJ, et al. Screening for Lung Cancer — 10 States , 2017. 2020;69.
Qin J, Saraiya M, Martinez G, Sawaya GF. Prevalence of Potentially Unnecessary Bimanual Pelvic Examinations and Papanicolaou Tests Among Adolescent Girls and Young Women Aged 15-20 Years in the United States. JAMA Intern Med [Internet]. American Medical Association; 2020 [cited 2020 Jul 1];180:274. Available from: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2758329
Calderwood AH, Anderson JC, Robinson CM, Butterly LF. Endoscopist Specialty Predicts the Likelihood of Recommending Cessation of Colorectal Cancer Screening in Older Adults. Am J Gastroenterol [Internet]. 2018 [cited 2019 Jun 20];113:1862–71. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30390031
Schoenborn NL, Huang J, Sheehan OC, Wolff JL, Roth DL, Boyd CM. Influence of Age, Health, and Function on Cancer Screening in Older Adults with Limited Life Expectancy. J Gen Intern Med [Internet]. 2019 [cited 2019 Jun 20];34:110–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30402822
Schonberg MA, Kistler CE, Pinheiro A, Jacobson AR, Aliberti GM, Karamourtopoulos M, et al. Effect of a Mammography Screening Decision Aid for Women 75 Years and Older. JAMA Intern Med [Internet]. American Medical Association; 2020 [cited 2020 Jul 1];180:831. Available from: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2764100
Rice K, Gressard L, DeGroff A, Gersten J, Robie J, Leadbetter S, et al. Increasing colonoscopy screening in disparate populations: Results from an evaluation of patient navigation in the New Hampshire Colorectal Cancer Screening Program. Cancer [Internet]. 2017 [cited 2019 Jun 20];123:3356–66. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28464213
Dougherty MK, Brenner AT, Crockett SD, Gupta S, Wheeler SB, Coker-Schwimmer M, et al. Evaluation of Interventions Intended to Increase Colorectal Cancer Screening Rates in the United States: A Systematic Review and Meta-analysis. JAMA Intern Med [Internet]. American Medical Association; 2018 [cited 2019 Dec 17];178:1645–58. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30326005
Liu D, Schuchard H, Burston B, Yamashita T, Albert S. Interventions to Reduce Healthcare Disparities in Cancer Screening Among Minority Adults: a Systematic Review. J Racial Ethn Heal Disparities [Internet]. 2020 [cited 2020 Jul 1]; Available from: http://link.springer.com/10.1007/s40615-020-00763-1
RL W, J L, JA T, DL M, T B, H G, et al. Effect of Mailed Human Papillomavirus Test Kits vs Usual Care Reminders on Cervical Cancer Screening Uptake, Precancer Detection, and Treatment: A Randomized Clinical Trial. JAMA Netw open [Internet]. JAMA Netw Open; 2019 [cited 2020 Jul 1];2. Available from: https://pubmed.ncbi.nlm.nih.gov/31693128/
A H, SS H, LE P, J C. Rural-urban Disparities in Colonoscopies After the Elimination of Patient Cost-Sharing by the Affordable Care Act. Prev Med (Baltim) [Internet]. Prev Med; 2019 [cited 2020 Jul 1];129. Available from: https://pubmed.ncbi.nlm.nih.gov/31669176/
Wouters OJ, McKee M, Luyten J. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. JAMA [Internet]. American Medical Association; 2020 [cited 2020 Jul 1];323:844. Available from: https://jamanetwork.com/journals/jama/fullarticle/2762311
Cancer drug approvals grew from 4% of U.S. total in the 1980s to 27% in 2010-18 – Tufts CSDD Impact Report September/October Vol. 21 No. 5. 2019;21:2019. Available from: https://csdd.tufts.edu/impact-reports/
Bhatt DL, Mehta C. Adaptive Designs for Clinical Trials. N Engl J Med [Internet]. Massachusetts Medical Society; 2016;375:65–74. Available from: http://dx.doi.org/10.1056/NEJMra1510061
Prowell TM, Theoret MR, Pazdur R. Seamless Oncology-Drug Development. N Engl J Med [Internet]. Massachusetts Medical Society; 2016;374:2001–3. Available from: http://dx.doi.org/10.1056/NEJMp1603747
Woodcock J, LaVange LM. Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. N Engl J Med [Internet]. 2017;377:62–70. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28679092
Kim S-H, Tanner A, Friedman DB, Foster C, Bergeron CD. Barriers to clinical trial participation: a comparison of rural and urban communities in South Carolina. J Community Health [Internet]. J Community Health; 2014 [cited 2020 Aug 3];39:562–71. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24310703
Seidler EM, Keshaviah A, Brown C, Wood E, Granick L, Kimball AB. Geographic distribution of clinical trials may lead to inequities in access. Clin Investig (Lond). 2014;4:373–80.
Loree JM, Anand S, Dasari A, Unger JM, Gothwal A, Ellis LM, et al. Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals from 2008 to 2018. JAMA Oncol. 2019;5:1–9.
Unger JM, Gralow JR, Albain KS, Ramsey SD, Hershman DL. Patient Income Level and Cancer Clinical Trial Participation: A Prospective Survey Study. JAMA Oncol. United States; 2016. page 137–9.
Bleyer A, Budd T, Montello M. Adolescents and young adults with cancer: the scope of the problem and criticality of clinical trials. Cancer. United States; 2006;107:1645–55.
Riviere P, Luterstein E, Kumar A, Vitzthum LK, Deka R, Sarkar RR, et al. Survival of African American and non‐Hispanic white men with prostate cancer in an equal‐access health care system. Cancer [Internet]. John Wiley & Sons, Ltd; 2020 [cited 2020 Jan 27];cncr.32666. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.32666
Fillmore NR, Yellapragada S V, Ifeorah C, Mehta A, Cirstea D, White PS, et al. With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study. Blood [Internet]. 2019 [cited 2019 Jun 20];133:2615–8. Available from: http://www.bloodjournal.org/lookup/doi/10.1182/blood.2019000406
Shapiro M, Chen Q, Huang Q, Boosalis VA, Yoon CH, Saund MS, et al. Associations of Socioeconomic Variables With Resection, Stage, and Survival in Patients With Early-Stage Pancreatic Cancer. JAMA Surg [Internet]. American Medical Association; 2016 [cited 2020 Jul 1];151:338. Available from: http://archsurg.jamanetwork.com/article.aspx?doi=10.1001/jamasurg.2015.4239
A O, K B, J D, D D, E S, SL S. Disparities in Neoadjuvant Radiation Dosing for Treatment of Rectal Cancer. Am J Surg [Internet]. Am J Surg; 2020 [cited 2020 Jul 1]; Available from: https://pubmed.ncbi.nlm.nih.gov/31959352/
NE F, SJ A, PJ S, DH H, TA D, JA K, et al. Disparities in Guideline-Concordant Treatment for Node-Positive, Non-Small Cell Lung Cancer Following Surgery. J Thorac Cardiovasc Surg [Internet]. J Thorac Cardiovasc Surg; 2020 [cited 2020 Jul 1];160. Available from: https://pubmed.ncbi.nlm.nih.gov/31924363/
MA F, TM W, R V. Racial Disparities in the Utilization of Novel Agents for Frontline Treatment of Multiple Myeloma. Clin Lymphoma Myeloma Leuk [Internet]. Clin Lymphoma Myeloma Leuk; 2020 [cited 2020 Jul 1]; Available from: https://pubmed.ncbi.nlm.nih.gov/32522440/
Verma V, Haque W, Cushman TR, Lin C, Simone CB, Chang JY, et al. Racial and Insurance-related Disparities in Delivery of Immunotherapy-type Compounds in the United States. J Immunother [Internet]. 2019 [cited 2019 Dec 17];42:55–64. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30628924
National Academies of Sciences E and M. Appropriate Use of Advanced Technologies for Radiation Therapy and Surgery in Oncology [Internet]. Nass SJ, Patlak M, editors. Washington, D.C.: National Academies Press; 2016 [cited 2020 Jul 1]. Available from: http://www.nap.edu/catalog/21859
JE M, JY W, DP R, JW C, W J, BY Y, et al. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial. JAMA Oncol [Internet]. JAMA Oncol; 2019 [cited 2020 Jul 1];5. Available from: https://pubmed.ncbi.nlm.nih.gov/31145418/
G G, VP G, AB B, DA L, L Z, AK N, et al. Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. Ann Surg [Internet]. Ann Surg; 2019 [cited 2020 Aug 14];270:340–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29596120
GV L, RPM S, S L, OE N, KF S, M G, et al. Neoadjuvant Dabrafenib Combined With Trametinib for Resectable, Stage IIIB-C, BRAF V600 Mutation-Positive Melanoma (NeoCombi): A Single-Arm, Open-Label, Single-Centre, Phase 2 Trial. Lancet Oncol [Internet]. Lancet Oncol; 2019 [cited 2020 Jul 1];20. Available from: https://pubmed.ncbi.nlm.nih.gov/31171444/
EA R, AM M, ACJ van A, C A, C B, BA van de W, et al. Identification of the Optimal Combination Dosing Schedule of Neoadjuvant Ipilimumab Plus Nivolumab in Macroscopic Stage III Melanoma (OpACIN-neo): A Multicentre, Phase 2, Randomised, Controlled Trial. Lancet Oncol [Internet]. Lancet Oncol; 2019 [cited 2020 Jul 1];20. Available from: https://pubmed.ncbi.nlm.nih.gov/31160251/
A K, C R, KP M, W S, SM D, S A, et al. Evaluation of 2014 Margin Guidelines on Re-Excision and Recurrence Rates After Breast Conserving Surgery: A Multi-Institution Retrospective Study. Breast [Internet]. Breast; 2020 [cited 2020 Jul 1];51. Available from: https://pubmed.ncbi.nlm.nih.gov/32199230/
The American Society of Breast Surgeons, Official Proceedings of 2019 annual Meeting. 2019;
JE G-O, NP W, DS D, JD C, DG K. Multidisciplinary Management of Oligometastatic Soft Tissue Sarcoma. Am Soc Clin Oncol Educ book Am Soc Clin Oncol Annu Meet [Internet]. Am Soc Clin Oncol Educ Book; 2018 [cited 2020 Jul 1];38. Available from: https://pubmed.ncbi.nlm.nih.gov/30231386/
Fernandez RAS, Lau RWH, Ho JYK, Yu PSY, Chow SCY, Wan IYP, et al. Evidence for surgical resections in oligometastatic lung cancer. J Thorac Dis [Internet]. AME Publications; 2019 [cited 2020 Jul 1];11:S969. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535472/
T R, F VC, CJ P, JE P, I B-R, JA L, et al. Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial. J Natl Cancer Inst [Internet]. J Natl Cancer Inst; 2017 [cited 2020 Jul 1];109. Available from: https://pubmed.ncbi.nlm.nih.gov/28376151/
Palma DA, Olson R, Harrow S, Gaede S, Louie A V, Haasbeek C, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet [Internet]. Elsevier; 2019 [cited 2020 Jul 1];393:2051–8. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32487-5/fulltext
Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, et al. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncol. 2020;21231.
Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, et al. Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. United States; 2018;4:e173501.
Gomez DR, Blumenschein GRJ, Lee JJ, Hernandez M, Ye R, Camidge DR, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. England; 2016;17:1672–82.
Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet (London, England) [Internet]. Elsevier; 2018 [cited 2019 Jun 20];392:2353–66. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30355464
Boevé LMS, Hulshof MCCM, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol [Internet]. 2019 [cited 2019 Jun 20];75:410–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30266309
Yeung AR, Pugh SL, Klopp AH, Gil KM, Wenzel L, Westin SN, et al. Improvement in Patient-Reported Outcomes With Intensity-Modulated Radiotherapy (RT) Compared With Standard RT: A Report From the NRG Oncology RTOG 1203 Study. J Clin Oncol. 2020;JCO.19.02381.
J T, V S, B B, V M, R L, MA S, et al. Lurbinectedin as Second-Line Treatment for Patients With Small-Cell Lung Cancer: A Single-Arm, Open-Label, Phase 2 Basket Trial. Lancet Oncol [Internet]. Lancet Oncol; 2020 [cited 2020 Jul 2];21. Available from: https://pubmed.ncbi.nlm.nih.gov/32224306/
Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children. N Engl J Med [Internet]. Massachusetts Medical Society; 2018 [cited 2019 Jun 20];378:731–9. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1714448
RC D, A D, L P-A, S S, AT S, AF F, et al. Entrectinib in Patients With Advanced or Metastatic NTRK Fusion-Positive Solid Tumours: Integrated Analysis of Three Phase 1-2 Trials. Lancet Oncol [Internet]. Lancet Oncol; 2020 [cited 2020 Jul 2];21. Available from: https://pubmed.ncbi.nlm.nih.gov/31838007/
AACR Project GENIE: Powering Precision Medicine Through An International Consortium. Cancer Discov. United States; 2017;
References 351-400
Gainor JF, Shaw AT. Novel Targets in Non-Small Cell Lung Cancer: ROS1 and RET Fusions. Oncologist [Internet]. Wiley-Blackwell; 2013 [cited 2020 Jul 2];18:865. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3720641/
Smeltzer MP, Wynes MW, Lantuejoul S, Soo R, Ramalingam SS, Varella-Garcia M, et al. The International Association for the Study of Lung Cancer (IASLC) Global Survey on Molecular Testing in Lung Cancer. J Thorac Oncol [Internet]. Elsevier; [cited 2020 Jul 2];0. Available from: https://www.jto.org/article/S1556-0864(20)30383-X/fulltext
Shaw AT, Ou S-HI, Bang Y-J, Camidge DR, Solomon BJ, Salgia R, et al. Crizotinib in ROS1 -Rearranged Non–Small-Cell Lung Cancer. N Engl J Med [Internet]. Massachusetts Medical Society; 2014 [cited 2020 Jul 2];371:1963–71. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1406766
A D, S S, R D, F B, MG K, AT S, et al. Entrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer: Integrated Analysis of Three Phase 1-2 Trials. Lancet Oncol [Internet]. Lancet Oncol; 2020 [cited 2020 Jul 2];21. Available from: https://pubmed.ncbi.nlm.nih.gov/31838015/
M S, R B, WT L, M de J, TM B, A A, et al. Molecular Correlates of Response to Capmatinib in Advanced Non-Small-Cell Lung Cancer: Clinical and Biomarker Results From a Phase I Trial. Ann Oncol Off J Eur Soc Med Oncol [Internet]. Ann Oncol; 2020 [cited 2020 Jul 2]; Available from: https://pubmed.ncbi.nlm.nih.gov/32240796/
Subbiah V, Gainor JF, Rahal R, Brubaker JD, Kim JL, Maynard M, et al. Precision Targeted Therapy with BLU-667 for RET -Driven Cancers. Cancer Discov [Internet]. American Association for Cancer Research; 2018 [cited 2020 Jul 2];8:836–49. Available from: http://cancerdiscovery.aacrjournals.org/lookup/doi/10.1158/2159-8290.CD-18-0338
Deng Y, Li H, Wang M, Li N, Tian T, Wu Y, et al. Global Burden of Thyroid Cancer From 1990 to 2017. JAMA Netw Open [Internet]. American Medical Association; 2020 [cited 2020 Jul 2];3:e208759. Available from: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2767676
Kraus WL. PARPs and ADP-Ribosylation: 50 Years … and Counting. Mol Cell. United States; 2015;58:902–10.
Lord CJ, Ashworth A. PARP Inhibitors: The First Synthetic Lethal Targeted Therapy. Science [Internet]. Europe PMC Funders; 2017 [cited 2020 Jul 2];355:1152. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175050/
Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature. England; 2012;481:287–94.
T G, P H, M R, E VC, T M, MJ H, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med [Internet]. N Engl J Med; 2019 [cited 2020 Jul 2];381. Available from: https://pubmed.ncbi.nlm.nih.gov/31157963/
J de B, J M, K F, F S, N S, S S, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med [Internet]. N Engl J Med; 2020 [cited 2020 Jul 2];382. Available from: https://pubmed.ncbi.nlm.nih.gov/32343890/
DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, et al. Breast cancer statistics, 2019. CA Cancer J Clin [Internet]. 2019 [cited 2019 Oct 4];caac.21583. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31577379
Modi S, Saura C, Yamashita T, Park YH, Kim S-B, Tamura K, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med [Internet]. Massachusetts Medical Society; 2020 [cited 2020 Jul 2];382:610–21. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1914510
RK M, S L, A O, E P, E H, SA H, et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med [Internet]. N Engl J Med; 2020 [cited 2020 Jul 2];382. Available from: https://pubmed.ncbi.nlm.nih.gov/31825569/
Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med [Internet]. Massachusetts Medical Society; 2018 [cited 2019 Jul 15];379:2108–21. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1809615
JP S, M E, W J, A S, JM P, IW F, et al. Acalabrutinib With or Without Obinutuzumab Versus Chlorambucil and Obinutuzmab for Treatment-Naive Chronic Lymphocytic Leukaemia (ELEVATE TN): A Randomised, Controlled, Phase 3 Trial. Lancet (London, England) [Internet]. Lancet; 2020 [cited 2020 Jul 2];395. Available from: https://pubmed.ncbi.nlm.nih.gov/32305093/
N K, M M, F C, G F, A G, JSP V, et al. Selinexor in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (SADAL): A Single-Arm, Multinational, Multicentre, Open-Label, Phase 2 Trial. Lancet Haematol [Internet]. Lancet Haematol; 2020 [cited 2020 Jul 2];7. Available from: https://pubmed.ncbi.nlm.nih.gov/32589977/
Palmer J, Mesa R. The role of fedratinib for the treatment of patients with primary orsecondary myelofibrosis. Ther Adv Hematol [Internet]. SAGE Publications; 2020 [cited 2020 Jul 2];11. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7232117/
Stacchiotti S, Schoffski P, Jones R, Agulnik M, Villalobos VM, Jahan TM, et al. Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients (pts) with epithelioid sarcoma (ES) (NCT02601950). J Clin Oncol [Internet]. American Society of Clinical Oncology; 2019 [cited 2020 Jul 2];37:11003–11003. Available from: http://ascopubs.org/doi/10.1200/JCO.2019.37.15_suppl.11003
Kim KH, Kim W, Howard TP, Vazquez F, Tsherniak A, Wu JN, et al. SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. Nat Med [Internet]. Nature Publishing Group; 2015 [cited 2020 Jul 2];21:1491–6. Available from: http://www.nature.com/articles/nm.3968
Quezado MM, Middleton LP, Bryant B, Lane K, Weiss SW, Merino MJ. Allelic loss on chromosome 22q in epithelioid sarcomas. Hum Pathol [Internet]. Hum Pathol; 1998 [cited 2020 Aug 3];29:604–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9635681
Versteege I, Sévenet N, Lange J, Rousseau-Merck MF, Ambros P, Handgretinger R, et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature [Internet]. Nature; 1998 [cited 2020 Aug 3];394:203–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9671307
Modena P, Lualdi E, Facchinetti F, Galli L, Teixeira MR, Pilotti S, et al. SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas. Cancer Res [Internet]. Cancer Res; 2005 [cited 2020 Aug 3];65:4012–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15899790
Wilson BG, Wang X, Shen X, McKenna ES, Lemieux ME, Cho Y-J, et al. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell [Internet]. NIH Public Access; 2010 [cited 2020 Aug 3];18:316–28. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20951942
Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet [Internet]. NIH Public Access; 2010 [cited 2020 Aug 3];42:181–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20081860
Knutson SK, Kawano S, Minoshima Y, Warholic NM, Huang K-C, Xiao Y, et al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Ther [Internet]. Mol Cancer Ther; 2014 [cited 2020 Aug 3];13:842–54. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24563539
Knutson SK, Warholic NM, Wigle TJ, Klaus CR, Allain CJ, Raimondi A, et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci U S A [Internet]. Proc Natl Acad Sci U S A; 2013 [cited 2020 Aug 3];110:7922–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23620515
SB R, SB B. Epigenetic Therapy for Epithelioid Sarcoma. Cell [Internet]. Cell; 2020 [cited 2020 Jul 2];181. Available from: https://pubmed.ncbi.nlm.nih.gov/32302562/
A I, JC S, M T, JM M, C L, A V, et al. Tazemetostat, an EZH2 Inhibitor, in Relapsed or Refractory B-cell non-Hodgkin Lymphoma and Advanced Solid Tumours: A First-In-Human, Open-Label, Phase 1 Study. Lancet Oncol [Internet]. Lancet Oncol; 2018 [cited 2020 Jul 2];19. Available from: https://pubmed.ncbi.nlm.nih.gov/29650362/
Kantarjian H, Issa J-PJ, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer [Internet]. Cancer; 2006 [cited 2020 Aug 3];106:1794–803. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16532500
Savona MR, Odenike O, Amrein PC, Steensma DP, DeZern AE, Michaelis LC, et al. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study. Lancet Haematol [Internet]. Lancet Haematol; 2019 [cited 2020 Aug 3];6:e194–203. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30926081
Garcia-Manero G, McCloskey J, Griffiths EA, Yee KWL, Zeidan AM, Al-Kali A, et al. Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine. Blood. 2019;134:846–846.
CL C, MC H. Molecular Pathobiology of Gastrointestinal Stromal Sarcomas. Annu Rev Pathol [Internet]. Annu Rev Pathol; 2008 [cited 2020 Jul 2];3. Available from: https://pubmed.ncbi.nlm.nih.gov/18039140/
Cassier PA, Fumagalli E, Rutkowski P, Schoffski P, Van Glabbeke M, Debiec-Rychter M, et al. Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era. Clin Cancer Res [Internet]. American Association for Cancer Research; 2012 [cited 2020 Jul 2];18:4458–64. Available from: http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0432.CCR-11-3025
JY B, C S, MC H, J Z, S B, H G, et al. Ripretinib in Patients With Advanced Gastrointestinal Stromal Tumours (INVICTUS): A Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial. Lancet Oncol [Internet]. Lancet Oncol; 2020 [cited 2020 Jul 2]; Available from: https://pubmed.ncbi.nlm.nih.gov/32511981/
Tap WD, Gelderblom H, Palmerini E, Desai J, Bauer S, Blay J-Y, et al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet [Internet]. Elsevier; 2019 [cited 2020 Jul 2];394:478–87. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)30764-0/fulltext
Lowery MA, Ptashkin R, Jordan E, Berger MF, Zehir A, Capanu M, et al. Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention. Clin Cancer Res [Internet]. American Association for Cancer Research; 2018 [cited 2020 Jul 2];24:4154–61. Available from: http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-18-0078
GK A-A, V S, A H, G V, D M, R A-R, et al. Pemigatinib for Previously Treated, Locally Advanced or Metastatic Cholangiocarcinoma: A Multicentre, Open-Label, Phase 2 Study. Lancet Oncol [Internet]. Lancet Oncol; 2020 [cited 2020 Jul 2];21. Available from: https://pubmed.ncbi.nlm.nih.gov/32203698/
Dombi E, Baldwin A, Marcus LJ, Fisher MJ, Weiss B, Kim A, et al. Activity of Selumetinib in Neurofibromatosis Type 1–Related Plexiform Neurofibromas. N Engl J Med [Internet]. Massachusetts Medical Society; 2016 [cited 2020 Jul 2];375:2550–60. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1605943
Polizzotto MN, Uldrick TS, Wyvill KM, Aleman K, Peer CJ, Bevans M, et al. Pomalidomide for Symptomatic Kaposi’s Sarcoma in People With and Without HIV Infection: A Phase I/II Study. J Clin Oncol [Internet]. American Society of Clinical Oncology; 2016 [cited 2020 Jul 2];34:4125–31. Available from: https://ascopubs.org/doi/10.1200/JCO.2016.69.3812
PM C-E, D S, P Y, Z A, K M, Y S, et al. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Cancer Res [Internet]. Cancer Res; 2016 [cited 2020 Jul 2];76. Available from: https://pubmed.ncbi.nlm.nih.gov/27013195/
JE R, PH O, AV B, BA M, EI H, EY Y, et al. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy. J Clin Oncol [Internet]. J Clin Oncol; 2019 [cited 2020 Jul 2];37. Available from: https://pubmed.ncbi.nlm.nih.gov/31356140/
J XY, JP H, C O, ST N, VM H-L, J T. Trends in Clinical Development for PD-1/PD-L1 Inhibitors. Nat Rev Drug Discov [Internet]. Nat Rev Drug Discov; 2020 [cited 2020 Jul 2];19. Available from: https://pubmed.ncbi.nlm.nih.gov/32127660/
Yu JX, Upadhaya S, Tatake R, Barkalow F, Hubbard-Lucey VM. Cancer cell therapies: the clinical trial landscape. Nat Rev Drug Discov [Internet]. 2020 [cited 2020 Jul 2]; Available from: http://www.nature.com/articles/d41573-020-00099-9
References 401-450
Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, et al. A new member of the immunoglobulin superfamily–CTLA-4. Nature. England; 1987;328:267–70.
Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. United States; 2002;99:12293–7.
Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. United States; 1995;3:541–7.
Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. United States; 1995;270:985–8.
Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. United States; 1999;11:141–51.
Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med. United States; 1991;174:561–9.
Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. United States; 2000;192:1027–34.
Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. United States; 1996;271:1734–6.
Sawyers CL, Abate-Shen C, Anderson KC, Barker A, Baselga J, Berger NA, et al. AACR Cancer Progress Report 2013. Clin Cancer Res. United States; 2013;19:S4-98.
Chen W, Swanson BJ, Frankel WL. Molecular genetics of microsatellite-unstable colorectal cancer for pathologists. Diagn Pathol [Internet]. BioMed Central; 2017 [cited 2020 Aug 3];12:24. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28259170
V M, MH T, C A, A O, J M, AL C, et al. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer. J Clin Oncol [Internet]. J Clin Oncol; 2020 [cited 2020 Jul 2]; Available from: https://pubmed.ncbi.nlm.nih.gov/32167863/
L P-A, M D, Y C, N R, K H, D T, et al. Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (CASPIAN): A Randomised, Controlled, Open-Label, Phase 3 Trial. Lancet (London, England) [Internet]. Lancet; 2019 [cited 2020 Jul 2];394. Available from: https://pubmed.ncbi.nlm.nih.gov/31590988/
K K, BC C, M T, M O, CY L, K C, et al. Nivolumab Versus Chemotherapy in Patients With Advanced Oesophageal Squamous Cell Carcinoma Refractory or Intolerant to Previous Chemotherapy (ATTRACTION-3): A Multicentre, Randomised, Open-Label, Phase 3 Trial. Lancet Oncol [Internet]. Lancet Oncol; 2019 [cited 2020 Jul 2];20. Available from: https://pubmed.ncbi.nlm.nih.gov/31582355/
MD H, L P-A, R BC, B Z, SW K, E CC, et al. Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med [Internet]. N Engl J Med; 2019 [cited 2020 Jul 2];381. Available from: https://pubmed.ncbi.nlm.nih.gov/31562796/
RS F, S Q, M I, PR G, M D, TY K, et al. Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med [Internet]. N Engl J Med; 2020 [cited 2020 Jul 2];382. Available from: https://pubmed.ncbi.nlm.nih.gov/32402160/
Gutzmer R, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England) [Internet]. Lancet; 2020 [cited 2020 Aug 3];395:1835–44. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32534646
June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science (80- ) [Internet]. 2018;359:1361–5. Available from: http://www.sciencemag.org/lookup/doi/10.1126/science.aar6711
Lim WA, June CH. The Principles of Engineering Immune Cells to Treat Cancer. Cell [Internet]. Elsevier Inc.; 2017;168:724–40. Available from: http://dx.doi.org/10.1016/j.cell.2017.01.016
Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin [Internet]. American Cancer Society; 2016 [cited 2020 Aug 3];66:443–59. Available from: http://doi.wiley.com/10.3322/caac.21357
Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med [Internet]. N Engl J Med; 2020 [cited 2020 Aug 3];382:1331–42. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32242358
M A, PG R, SV R, J S-M, M B, I S, et al. Isatuximab Plus Pomalidomide and Low-Dose Dexamethasone Versus Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma (ICARIA-MM): A Randomised, Multicentre, Open-Label, Phase 3 Study. Lancet (London, England) [Internet]. Lancet; 2019 [cited 2020 Jul 2];394. Available from: https://pubmed.ncbi.nlm.nih.gov/31735560/
G S, J D, E GB, O T, W J, AM L, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol [Internet]. Lancet Oncol; 2020 [cited 2020 Aug 15];21. Available from: https://pubmed.ncbi.nlm.nih.gov/32511983/
Centers for Disease Control and Prevention. Cancer Survivorship—United States, 1971–2001. Morbitity Mortal Wkly Rep. 2004;53:526–529.
Ekwueme DU, Zhao J, Rim SH, Moor JS De, Zheng Z, Khushalani JS, et al. Annual Out-of-Pocket Expenditures and Financial Hardship Among Cancer Survivors Aged 18 – 64 Years — United States , 2011 – 2016. 2019;68:2011–6.
Gilligan AM, Alberts DS, Roe DJ, Skrepnek GH. Death or Debt? National Estimates of Financial Toxicity in Persons with Newly-Diagnosed Cancer. Am J Med [Internet]. Elsevier Inc.; 2018;131:1187-1199.e5. Available from: https://doi.org/10.1016/j.amjmed.2018.05.020
Han X, Zhao J, Zheng Z, de Moor JS, Virgo KS, Yabroff KR. Medical Financial Hardship Intensity and Financial Sacrifice Associated with Cancer in the United States. Cancer Epidemiol Biomarkers Prev [Internet]. American Association for Cancer Research; 2020 [cited 2020 Jul 3];29:308–17. Available from: http://cebp.aacrjournals.org/lookup/doi/10.1158/1055-9965.EPI-19-0460
Hastert TA, Kyko JM, Reed AR, Harper FWK, Beebe-Dimmer JL, Baird TE, et al. Financial Hardship and Quality of Life among African American and White Cancer Survivors: The Role of Limiting Care Due to Cost. Cancer Epidemiol Biomarkers Prev [Internet]. American Association for Cancer Research; 2019 [cited 2019 Dec 17];28:1202–11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31061097
Cha AE, Cohen RA. Problems Paying Medical Bills, 2018. NCHS Data Brief. 2020;1–8.
Ketterl TG, Syrjala KL, Casillas J, Jacobs LA, Palmer SC, McCabe MS, et al. Lasting effects of cancer and its treatment on employment and finances in adolescent and young adult cancer survivors. Cancer [Internet]. 2019 [cited 2019 Jun 20];125:1908–17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30707763
IC H, N B, TM B, JL K, KR K, D S, et al. Determinants and Consequences of Financial Hardship Among Adult Survivors of Childhood Cancer: A Report From the St. Jude Lifetime Cohort Study. J Natl Cancer Inst [Internet]. J Natl Cancer Inst; 2019 [cited 2020 Jul 3];111. Available from: https://pubmed.ncbi.nlm.nih.gov/30085213/
S E, BN T, JB C, SJ L, D S, BT L. Racial Disparities in Postmastectomy Breast Reconstruction: National Trends in Utilization From 2005 to 2014. Cancer [Internet]. Cancer; 2018 [cited 2020 Jul 3];124. Available from: https://pubmed.ncbi.nlm.nih.gov/29660760/
Lee K, Gani F, Canner JK, Johnston FM. Racial Disparities in Utilization of Palliative Care Among Patients Admitted With Advanced Solid Organ Malignancies. Am J Hosp Palliat Med [Internet]. SAGE PublicationsSage CA: Los Angeles, CA; 2020 [cited 2020 Jul 3];104990912092277. Available from: http://journals.sagepub.com/doi/10.1177/1049909120922779
Andrykowski MA, Aarts MJ, van de Poll-Franse L V., Mols F, Slooter GD, Thong MSY. Low socioeconomic status and mental health outcomes in colorectal cancer survivors: disadvantage? advantage? … or both? Psychooncology [Internet]. 2013 [cited 2019 Jun 19];22:2462–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23712928
Weaver KE, Geiger AM, Lu L, Case LD. Rural-urban disparities in health status among US cancer survivors. Cancer [Internet]. John Wiley & Sons, Ltd; 2013 [cited 2019 Jul 16];119:1050–7. Available from: http://doi.wiley.com/10.1002/cncr.27840
Barile JP, Reeve BB, Smith AW, Zack MM, Mitchell SA, Kobau R, et al. Monitoring population health for Healthy People 2020: evaluation of the NIH PROMIS® Global Health, CDC Healthy Days, and satisfaction with life instruments. Qual Life Res [Internet]. 2013 [cited 2019 Jun 20];22:1201–11. Available from: http://link.springer.com/10.1007/s11136-012-0246-z
Shapiro CL. Cancer Survivorship. Longo DL, editor. N Engl J Med [Internet]. 2018 [cited 2019 Jun 20];379:2438–50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30575480
DA M, G H, KK N, MJ E, Y Y, D D, et al. Major Cardiac Events for Adult Survivors of Childhood Cancer Diagnosed Between 1970 and 1999: Report From the Childhood Cancer Survivor Study Cohort. BMJ [Internet]. BMJ; 2020 [cited 2020 Jul 3];368. Available from: https://pubmed.ncbi.nlm.nih.gov/31941657/
Yeh JM, Ward ZJ, Chaudhry A, Liu Q, Yasui Y, Armstrong GT, et al. Life Expectancy of Adult Survivors of Childhood Cancer Over 3 Decades. JAMA Oncol [Internet]. American Medical Association; 2020 [cited 2020 Jul 3];6:350. Available from: https://jamanetwork.com/journals/jamaoncology/fullarticle/2757844
Weaver KE, Forsythe LP, Reeve BB, Alfano CM, Rodriguez JL, Sabatino SA, et al. Mental and physical health-related quality of life among U.S. cancer survivors: population estimates from the 2010 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev [Internet]. NIH Public Access; 2012 [cited 2019 Jun 20];21:2108–17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23112268
Hoerger M, Wayser GR, Schwing G, Suzuki A, Perry LM. Impact of Interdisciplinary Outpatient Specialty Palliative Care on Survival and Quality of Life in Adults With Advanced Cancer: A Meta-Analysis of Randomized Controlled Trials. Ann Behav Med [Internet]. 2019 [cited 2019 Jun 20];53:674–85. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30265282
McTiernan A, Friedenreich CM, Katzmarzyk, PT, Powell, KE, Macko R, Buchner D, et al. Physical Activity in Cancer Prevention and Survival. Med Sci Sport Exerc [Internet]. 2019 [cited 2019 Jun 20];51:1252–61. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31095082
Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin [Internet]. American Cancer Society; 2019 [cited 2019 Jun 19];caac.21565. Available from: https://onlinelibrary.wiley.com/doi/abs/10.3322/caac.21565
Blanchard CM, Courneya KS, Stein K, American Cancer Society’s SCS-II. Cancer Survivors’ Adherence to Lifestyle Behavior Recommendations and Associations With Health-Related Quality of Life: Results From the American Cancer Society’s SCS-II. J Clin Oncol [Internet]. 2008 [cited 2019 Jun 20];26:2198–204. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18445845
United States Department of Health and Human Services. The Health Consequences of Smoking—50 Years of Progress A Report of the Surgeon General. A Rep Surg Gen. 2014;1081.
JL W, B T, C SL, S L. Smoking Versus Quitting and Fear of Cancer Recurrence 9 Years After Diagnosis in the American Cancer Society’s Longitudinal Study of Cancer Survivors-I (SCS-I). Cancer [Internet]. Cancer; 2019 [cited 2020 Jul 3];125. Available from: https://pubmed.ncbi.nlm.nih.gov/31390060/
Westmaas JL, Alcaraz KI, Berg CJ, Stein KD. Prevalence and Correlates of Smoking and Cessation-Related Behavior among Survivors of Ten Cancers: Findings from a Nationwide Survey Nine Years after Diagnosis. Cancer Epidemiol Biomarkers & Prev [Internet]. 2014;23:1783 LP – 1792. Available from: http://cebp.aacrjournals.org/content/23/9/1783.abstract
Toll BA, Brandon TH, Gritz ER, Warren GW, Herbst RS. Assessing tobacco use by cancer patients and facilitating cessation: an American Association for Cancer Research policy statement. Clin Cancer Res. United States; 2013;19:1941–8.
JB B, NL W, JL H, B S, K M, D K, et al. A Smartphone App Designed to Help Cancer Patients Stop Smoking: Results From a Pilot Randomized Trial on Feasibility, Acceptability, and Effectiveness. JMIR Form Res [Internet]. JMIR Form Res; 2020 [cited 2020 Jul 3];4. Available from: https://pubmed.ncbi.nlm.nih.gov/31951215/
References 451-500
JL W, J B-J, PS H, J K, LC A. Randomised Controlled Trial of Stand-Alone Tailored Emails for Smoking Cessation. Tob Control [Internet]. Tob Control; 2018 [cited 2020 Jul 3];27. Available from: https://pubmed.ncbi.nlm.nih.gov/28522745/
CM F, HK N, MS F, KS C. Physical Activity and Cancer Outcomes: A Precision Medicine Approach. Clin Cancer Res [Internet]. Clin Cancer Res; 2016 [cited 2020 Jul 3];22. Available from: https://pubmed.ncbi.nlm.nih.gov/27407093/
MS F, KA K, KS C, SE M, Q W, CM F. Associations of Postdiagnosis Physical Activity and Change From Prediagnosis Physical Activity With Quality of Life in Prostate Cancer Survivors. Cancer Epidemiol Biomarkers Prev [Internet]. Cancer Epidemiol Biomarkers Prev; 2017 [cited 2020 Jul 3];26. Available from: https://pubmed.ncbi.nlm.nih.gov/27677728/
Mishra SI, Scherer RW, Geigle PM, Berlanstein DR, Topaloglu O, Gotay CC, et al. Exercise interventions on health-related quality of life for cancer survivors. Cochrane Database Syst Rev [Internet]. 2012 [cited 2019 Jun 20];CD007566. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22895961
Mishra SI, Scherer RW, Snyder C, Geigle P, Gotay C. The Effectiveness of Exercise Interventions for Improving Health-Related Quality of Life From Diagnosis Through Active Cancer Treatment. Oncol Nurs Forum [Internet]. 2015 [cited 2019 Jun 20];42:E33–53. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25542333
Mustian KM, Alfano CM, Heckler C, Kleckner AS, Kleckner IR, Leach CR, et al. Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue. JAMA Oncol [Internet]. 2017 [cited 2019 Jun 20];3:961. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28253393
Craft LL, VanIterson EH, Helenowski IB, Rademaker AW, Courneya KS. Exercise Effects on Depressive Symptoms in Cancer Survivors: A Systematic Review and Meta-Analysis. Cancer Epidemiol Biomarkers Prev [Internet]. NIH Public Access; 2012 [cited 2019 Jun 20];21:3. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3253916/
ROGERS LQ, COURNEYA KS, OSTER RA, ANTON PM, ROBBS RS, FORERO A, et al. Physical Activity and Sleep Quality in Breast Cancer Survivors. Med Sci Sport Exerc [Internet]. 2017 [cited 2019 Jun 20];49:2009–15. Available from: http://insights.ovid.com/crossref?an=00005768-201710000-00006
Irwin ML, Cartmel B, Gross CP, Ercolano E, Li F, Yao X, et al. Randomized Exercise Trial of Aromatase Inhibitor–Induced Arthralgia in Breast Cancer Survivors. J Clin Oncol [Internet]. American Society of Clinical Oncology; 2015 [cited 2019 Jun 20];33:1104. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4372849/
Kleckner IR, Kamen C, Gewandter JS, Mohile NA, Heckler CE, Culakova E, et al. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Support Care Cancer [Internet]. 2018 [cited 2019 Jun 20];26:1019–28. Available from: http://link.springer.com/10.1007/s00520-017-4013-0
Northey JM, Cherbuin N, Pumpa KL, Smee DJ, Rattray B. Exercise interventions for cognitive function in adults older than 50: a systematic review with meta-analysis. Br J Sports Med [Internet]. BMJ Publishing Group Ltd and British Association of Sport and Exercise Medicine; 2018 [cited 2019 Jun 20];52:154–60. Available from: https://bjsm.bmj.com/content/52/3/154
Scott JM, Zabor EC, Schwitzer E, Koelwyn GJ, Adams SC, Nilsen TS, et al. Efficacy of Exercise Therapy on Cardiorespiratory Fitness in Patients With Cancer: A Systematic Review and Meta-Analysis. J Clin Oncol [Internet]. 2018 [cited 2019 Jun 20];36:2297–305. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29894274
Sturgeon KM, Deng L, Bluethmann SM, Zhou S, Trifiletti DM, Jiang C, et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019;40:3889–97.
Van Blarigan EL, Fuchs CS, Niedzwiecki D, Zhang S, Saltz LB, Mayer RJ, et al. Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis. JAMA Oncol [Internet]. 2018 [cited 2018 May 7]; Available from: http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2018.0126
Song M, Wu K, Meyerhardt JA, Ogino S, Wang M, Fuchs CS, et al. Fiber Intake and Survival After Colorectal Cancer Diagnosis. JAMA Oncol. United States; 2018;4:71–9.
MS F, KS C, KA K, SE M, CM F. Post-diagnosis Alcohol Intake and Prostate Cancer Survival: A Population-Based Cohort Study. Int J cancer [Internet]. Int J Cancer; 2018 [cited 2020 Jul 3];143. Available from: https://pubmed.ncbi.nlm.nih.gov/29435976/
Kwan ML, Kushi LH, Weltzien E, Tam EK, Castillo A, Sweeney C, et al. Alcohol Consumption and Breast Cancer Recurrence and Survival Among Women With Early-Stage Breast Cancer: The Life After Cancer Epidemiology Study. J Clin Oncol [Internet]. American Society of Clinical Oncology; 2010 [cited 2020 Jul 3];28:4410. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988633/
Sanford NN, Sher DJ, Xu X, Ahn C, D’Amico A V., Aizer AA, et al. Alcohol use among patients with cancer and survivors in the United States, 2000–2017. JNCCN J Natl Compr Cancer Netw. 2020;18:69–79.
Greer JA, Jacobs JM, El-Jawahri A, Nipp RD, Gallagher ER, Pirl WF, et al. Role of Patient Coping Strategies in Understanding the Effects of Early Palliative Care on Quality of Life and Mood. J Clin Oncol. United States; 2018;36:53–60.
P M, C N, RS M. Economics of Palliative Care for Cancer: Interpreting Current Evidence, Mapping Future Priorities for Research. J Clin Oncol [Internet]. J Clin Oncol; 2020 [cited 2020 Jul 3];38. Available from: https://pubmed.ncbi.nlm.nih.gov/32023166/
Hui D, De La Rosa A, Chen J, Dibaj S, Delgado Guay M, Heung Y, et al. State of palliative care services at US cancer centers: An updated national survey. Cancer [Internet]. John Wiley & Sons, Ltd; 2020 [cited 2020 Jul 3];126:2013–23. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.32738
Dionne-Odom JN, Ornstein KA, Kent EE. What do family caregivers know about palliative care? Results from a national survey. Palliat Support Care [Internet]. NIH Public Access; 2019 [cited 2020 Jul 3];17:643. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783327/
Hoerger M, Perry LM, Gramling R, Epstein RM, Duberstein PR. Does educating patients about the Early Palliative Care Study increase preferences for outpatient palliative cancer care? Findings from Project EMPOWER. Health Psychol [Internet]. NIH Public Access; 2017 [cited 2020 Jul 3];36:538. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444973/
Arrieta O, Angulo LP, Nunez-Valencia C, Dorantes-Gallareta Y, Macedo EO, Martinez-Lopez D, et al. Association of depression and anxiety on quality of life, treatment adherence, and prognosis in patients with advanced non-small cell lung cancer. Ann Surg Oncol. United States; 2013;20:1941–8.
Brown KW, Levy AR, Rosberger Z, Edgar L. Psychological distress and cancer survival: a follow-up 10 years after diagnosis. Psychosom Med. United States; 2003;65:636–43.
Pinquart M, Duberstein PR. Associations of social networks with cancer mortality: a meta-analysis. Crit Rev Oncol Hematol [Internet]. NIH Public Access; 2010 [cited 2020 Aug 3];75:122–37. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19604706
SA J, PV S, TL T, AA C, KA B-C, LF B, et al. Acceptance and Commitment Therapy for Breast Cancer Survivors With Fear of Cancer Recurrence: A 3-arm Pilot Randomized Controlled Trial. Cancer [Internet]. Cancer; 2020 [cited 2020 Jul 3];126. Available from: https://pubmed.ncbi.nlm.nih.gov/31539169/
B Z, M K, L S. First Descents, an Adventure Program for Young Adults With Cancer: Who Benefits? Support Care Cancer [Internet]. Support Care Cancer; 2017 [cited 2020 Jul 3];25. Available from: https://pubmed.ncbi.nlm.nih.gov/28656467/
Kline RM, Arora NK, Bradley CJ, Brauer ER, Graves DL, Lunsford NB, et al. Long-Term Survivorship Care After Cancer Treatment – Summary of a 2017 National Cancer Policy Forum Workshop. JNCI J Natl Cancer Inst [Internet]. Oxford Academic; 2018 [cited 2020 Jul 3];110:1300–10. Available from: https://academic.oup.com/jnci/article/110/12/1300/5216319
L N, DM O, SV H. Integrating Primary Care Providers in the Care of Cancer Survivors: Gaps in Evidence and Future Opportunities. Lancet Oncol [Internet]. Lancet Oncol; 2017 [cited 2020 Jul 3];18. Available from: https://pubmed.ncbi.nlm.nih.gov/28049575/
Zhao Y, Brettle A, Qiu L. The Effectiveness of Shared Care in Cancer Survivors—A Systematic Review. Int J Integr Care [Internet]. 2018 [cited 2019 Jul 29];18:2. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30483035
Alfano CM, Mayer DK, Bhatia S, Maher J, Scott JM, Nekhlyudov L, et al. Implementing personalized pathways for cancer follow‐up care in the United States: Proceedings from an American Cancer Society–American Society of Clinical Oncology summit. CA Cancer J Clin [Internet]. American Cancer Society; 2019 [cited 2019 Jul 29];69:234–47. Available from: https://onlinelibrary.wiley.com/doi/abs/10.3322/caac.21558
Kent EE, Dionne-Odom JN. Population-Based Profile of Mental Health and Support Service Need Among Family Caregivers of Adults With Cancer. J Oncol Pract [Internet]. American Society of Clinical Oncology; 2019 [cited 2019 Jun 20];15:e122–31. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30496020
Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med [Internet]. Springer US; 2019;25:44–56. Available from: http://www.nature.com/articles/s41591-018-0300-7
P W, X X, JR GB, TM B, M T, F X, et al. Development and Validation of a Deep-Learning Algorithm for the Detection of Polyps During Colonoscopy. Nat Biomed Eng [Internet]. Nat Biomed Eng; 2018 [cited 2020 Jul 2];2. Available from: https://pubmed.ncbi.nlm.nih.gov/31015647/
L H, D B, S A, Z X, K Y, MP H, et al. An Observational Study of Deep Learning and Automated Evaluation of Cervical Images for Cancer Screening. J Natl Cancer Inst [Internet]. J Natl Cancer Inst; 2019 [cited 2020 Jul 2];111. Available from: https://pubmed.ncbi.nlm.nih.gov/30629194/
Ardila D, Kiraly AP, Bharadwaj S, Choi B, Reicher JJ, Peng L, et al. End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography. Nat Med [Internet]. Nature Publishing Group; 2019 [cited 2020 Jul 2];25:954–61. Available from: http://www.nature.com/articles/s41591-019-0447-x
Ström P, Kartasalo K, Olsson H, Solorzano L, Delahunt B, Berney DM, et al. Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study. Lancet Oncol. 2020;21:222–32.
Hollon TC, Pandian B, Adapa AR, Urias E, Save A V., Khalsa SSS, et al. Near real-time intraoperative brain tumor diagnosis using stimulated Raman histology and deep neural networks. Nat Med. 2020;26:52–8.
G S, Y B, R S, I D, Z G, R K. Artificial Intelligence Algorithms to Assess Hormonal Status From Tissue Microarrays in Patients With Breast Cancer. JAMA Netw open [Internet]. JAMA Netw Open; 2019 [cited 2020 Jul 2];2. Available from: https://pubmed.ncbi.nlm.nih.gov/31348505/
Coudray N, Ocampo PS, Sakellaropoulos T, Narula N, Snuderl M, Fenyö D, et al. Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning. Nat Med [Internet]. Nature Publishing Group; 2018 [cited 2020 Jul 2];24:1559–67. Available from: http://www.nature.com/articles/s41591-018-0177-5
Ho D. Artificial intelligence in cancer therapy. Science (80- ). 2020;367:982–3.
Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov [Internet]. NIH Public Access; 2019 [cited 2020 Jul 29];18:463–77. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30976107
T B, T B, JH D, YA E, EJ G, AL G, et al. AI Meets Exascale Computing: Advancing Cancer Research With Large-Scale High Performance Computing. Front Oncol [Internet]. Front Oncol; 2019 [cited 2020 Jul 2];9. Available from: https://pubmed.ncbi.nlm.nih.gov/31632915/
Dercle L, Fronheiser M, Lu L, Du S, Hayes W, Leung DK, et al. Identification of Non–Small Cell Lung Cancer Sensitive to Systemic Cancer Therapies Using Radiomics. Clin Cancer Res [Internet]. American Association for Cancer Research; 2020 [cited 2020 Jul 2]; Available from: https://clincancerres.aacrjournals.org/content/early/2020/03/16/1078-0432.CCR-19-2942
Thomas F, Donnadieu E, Charriere GM, Jacqueline C, Tasiemski A, Pujol P, et al. Is adaptive therapy natural? PLoS Biol [Internet]. Public Library of Science; 2018 [cited 2020 Aug 3];16:e2007066. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30278037
References 501-547
Gatenby RA, Silva AS, Gillies RJ, Frieden BR. Adaptive therapy. Cancer Res [Internet]. NIH Public Access; 2009 [cited 2020 Aug 3];69:4894–903. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19487300
RB P, C M, C C, SH R, J B, ME D, et al. Machine Learning Approaches to Predict 6-Month Mortality Among Patients With Cancer. JAMA Netw open [Internet]. JAMA Netw Open; 2019 [cited 2020 Jul 2];2. Available from: https://pubmed.ncbi.nlm.nih.gov/31651973/
Vyas DA, Eisenstein LG, Jones DS. Hidden in Plain Sight — Reconsidering the Use of Race Correction in Clinical Algorithms. Malina D, editor. N Engl J Med [Internet]. Massachusetts Medical Society; 2020 [cited 2020 Jul 2];NEJMms2004740. Available from: http://www.nejm.org/doi/10.1056/NEJMms2004740
Obermeyer Z, Powers B, Vogeli C, Mullainathan S. Dissecting racial bias in an algorithm used to manage the health of populations. Science [Internet]. American Association for the Advancement of Science; 2019 [cited 2019 Dec 18];366:447–53. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31649194
Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, et al. Circulating Tumor DNA Analysis in Patients With Cancer : American Society of Clinical Oncology and College of American Pathologists Joint Review. 2019;36.
Shen SY, Singhania R, Fehringer G, Chakravarthy A, Roehrl MHA, Chadwick D, et al. Sensitive tumour detection and classification using plasma cell-free DNA methylomes. Nature [Internet]. Nature Publishing Group; 2018 [cited 2019 Jun 3];563:579–83. Available from: http://www.nature.com/articles/s41586-018-0703-0
Cristiano S, Leal A, Phallen J, Fiksel J, Adleff V, Bruhm DC, et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature [Internet]. 2019 [cited 2019 Jun 20];570:385–9. Available from: http://www.nature.com/articles/s41586-019-1272-6
Panditharatna E, Kilburn LB, Aboian MS, Kambhampati M, Gordish-Dressman H, Magge SN, et al. Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid Biopsy. Clin Cancer Res [Internet]. 2018 [cited 2019 Jun 20];24:5850–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30322880
Chen X, Gole J, Gore A, He Q, Lu M, Min J, et al. Non-invasive early detection of cancer four years before conventional diagnosis using a blood test. Nat Commun [Internet]. Nature Publishing Group; 2020 [cited 2020 Aug 3];11:3475. Available from: http://www.nature.com/articles/s41467-020-17316-z
Li BT, Janku F, Jung B, Hou C, Madwani K, Alden R, et al. Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers : results from the Actionable Genome Consortium. 2019;1–7.
Wang D-S, Liu Z-X, Lu Y-X, Bao H, Wu X, Zeng Z-L, et al. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut [Internet]. 2019 [cited 2019 Jun 20];68:1152–61. Available from: http://gut.bmj.com/lookup/doi/10.1136/gutjnl-2018-316522
Leighl NB, Page RD, Raymond VM, Daniel DB, Divers SG, Reckamp KL, et al. Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer. Clin Cancer Res [Internet]. American Association for Cancer Research; 2019 [cited 2019 Jun 20]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/30988079
Chemi F, Rothwell DG, McGranahan N, Gulati S, Abbosh C, Pearce SP, et al. Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse. Nat Med [Internet]. Nature Publishing Group; 2019 [cited 2020 Jul 2];25:1534–9. Available from: http://www.nature.com/articles/s41591-019-0593-1
Tie J, Cohen JD, Wang Y, Christie M, Simons K, Lee M, et al. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer. JAMA Oncol [Internet]. American Medical Association; 2019 [cited 2020 Jul 2];5:1710. Available from: https://jamanetwork.com/journals/jamaoncology/fullarticle/2752788
Radovich M, Jiang G, Hancock BA, Chitambar C, Nanda R, Falkson C, et al. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial. JAMA Oncol [Internet]. JAMA Oncol; 2020 [cited 2020 Aug 3]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/32644110
Tavaré R, McCracken MN, Zettlitz KA, Knowles SM, Salazar FB, Olafsen T, et al. Engineered antibody fragments for immuno-PET imaging of endogenous CD8+ T cells in vivo. Proc Natl Acad Sci U S A [Internet]. National Academy of Sciences; 2014 [cited 2020 Jul 2];111:1108. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3903195/
M R, MW L, VL V, A D, Y Z, TH N, et al. Immuno-PET Identifies the Myeloid Compartment as a Key Contributor to the Outcome of the Antitumor Response Under PD-1 Blockade. Proc Natl Acad Sci U S A [Internet]. Proc Natl Acad Sci U S A; 2019 [cited 2020 Jul 2];116. Available from: https://pubmed.ncbi.nlm.nih.gov/31375632/
Donnelly DJ, Smith RA, Morin P, Lipovšek D, Gokemeijer J, Cohen D, et al. Synthesis and Biologic Evaluation of a Novel 18F-Labeled Adnectin as a PET Radioligand for Imaging PD-L1 Expression. J Nucl Med [Internet]. Society of Nuclear Medicine; 2018 [cited 2020 Jul 2];59:529–35. Available from: http://jnm.snmjournals.org/content/59/3/529
Niemeijer AN, Leung D, Huisman MC, Bahce I, Hoekstra OS, van Dongen GAMS, et al. Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. Nat Commun [Internet]. Nature Publishing Group; 2018 [cited 2020 Jul 2];9:4664. Available from: http://www.nature.com/articles/s41467-018-07131-y
Sautès-Fridman C, Petitprez F, Calderaro J, Fridman WH. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer [Internet]. Nature Publishing Group; 2019 [cited 2020 Jul 2];19:307–25. Available from: http://www.nature.com/articles/s41568-019-0144-6
Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature [Internet]. Nature Publishing Group; 2020 [cited 2020 Jul 2];577:561–5. Available from: http://www.nature.com/articles/s41586-019-1914-8
Torrejon DY, Abril-Rodriguez G, Champhekar AS, Tsoi J, Campbell KM, Kalbasi A, et al. Overcoming genetically-based resistance mechanisms to PD-1 blockade. Cancer Discov [Internet]. American Association for Cancer Research; 2020 [cited 2020 Jul 2]; Available from: https://cancerdiscovery.aacrjournals.org/content/early/2020/05/22/2159-8290.CD-19-1409
Diab A, Tannir NM, Bentebibel S-E, Hwu P, Papadimitrakopoulou V, Haymaker C, et al. Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02). Cancer Discov [Internet]. American Association for Cancer Research; 2020 [cited 2020 Jul 2]; Available from: https://cancerdiscovery.aacrjournals.org/content/early/2020/05/20/2159-8290.CD-19-1510
Aspeslagh S, Postel-Vinay S, Rusakiewicz S, Soria J-C, Zitvogel L, Marabelle A. Rationale for anti-OX40 cancer immunotherapy. Eur J Cancer [Internet]. Elsevier; 2016 [cited 2020 Jul 2];52:50–66. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0959804915008205
Peng W, Williams LJ, Xu C, Melendez B, McKenzie JA, Chen Y, et al. Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8 + T Cells and Synergizes with PI3Kβ Inhibition in PTEN Loss Melanoma. Clin Cancer Res [Internet]. American Association for Cancer Research; 2019 [cited 2020 Jul 2];25:6406–16. Available from: http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-19-1259
Gaspar M, Pravin J, Rodrigues L, Uhlenbroich S, Everett KL, Wollerton F, et al. A CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity That Is Dependent on Target Co-Engagement. Cancer Immunol Res [Internet]. American Association for Cancer Research; 2020 [cited 2020 Jul 2]; Available from: https://cancerimmunolres.aacrjournals.org/content/early/2020/04/07/2326-6066.CIR-19-0798
C L, H M, Y H. Applications and Explorations of CRISPR/Cas9 in CAR T-cell Therapy. Brief Funct Genomics [Internet]. Brief Funct Genomics; 2020 [cited 2020 Jul 2];19. Available from: https://pubmed.ncbi.nlm.nih.gov/31950135/
Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, et al. CRISPR-engineered T cells in patients with refractory cancer. Science (80- ) [Internet]. American Association for the Advancement of Science; 2020 [cited 2020 Jul 2];367. Available from: https://science.sciencemag.org/content/367/6481/eaba7365
Wang G, Chow RD, Bai Z, Zhu L, Errami Y, Dai X, et al. Multiplexed activation of endogenous genes by CRISPRa elicits potent antitumor immunity. Nat Immunol [Internet]. Nature Publishing Group; 2019 [cited 2020 Jul 2];20:1494–505. Available from: http://www.nature.com/articles/s41590-019-0500-4
Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma. N Engl J Med [Internet]. Massachusetts Medical Society ; 1988 [cited 2020 Jul 2];319:1676–80. Available from: http://www.nejm.org/doi/abs/10.1056/NEJM198812223192527
N Z, H C, M B, H X, YC L, Z Z, et al. Immune Recognition of Somatic Mutations Leading to Complete Durable Regression in Metastatic Breast Cancer. Nat Med [Internet]. Nat Med; 2018 [cited 2020 Jul 2];24. Available from: https://pubmed.ncbi.nlm.nih.gov/29867227/
E T, PF R, YC L, TD P, JJ G, L J, et al. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. N Engl J Med [Internet]. N Engl J Med; 2016 [cited 2020 Jul 2];375. Available from: https://pubmed.ncbi.nlm.nih.gov/27959684/
DC D, A P, PF R, JJ G, TD P, BC P, et al. T-cell Responses to TP53 “Hotspot” Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers. Clin Cancer Res [Internet]. Clin Cancer Res; 2018 [cited 2020 Jul 2];24. Available from: https://pubmed.ncbi.nlm.nih.gov/29853601/
Barkal AA, Brewer RE, Markovic M, Kowarsky M, Barkal SA, Zaro BW, et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature [Internet]. Nature Publishing Group; 2019 [cited 2020 Jul 2];572:392–6. Available from: http://www.nature.com/articles/s41586-019-1456-0
S H, VE K, BH H, C Z, MA B, BL K, et al. Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer. Cancer Cell [Internet]. Cancer Cell; 2020 [cited 2020 Jul 2];37. Available from: https://pubmed.ncbi.nlm.nih.gov/32183949/
Liu E, Marin D, Banerjee P, MacApinlac HA, Thompson P, Basar R, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382:545–53.
June CH, Warshauer JT, Bluestone JA. Is autoimmunity the Achilles’ heel of cancer immunotherapy? Nat Med [Internet]. 2017 [cited 2019 Jun 21];23:540–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28475571
Lowy: Paylines are dropping because NCI is drawing more applicants who would’ve previously gone elsewhere – The Cancer Letter [Internet]. [cited 2020 Aug 3]. Available from: https://cancerletter.com/articles/20191206_1/
